Wayne State University
Wayne State University Dissertations

1-1-2012

Sex differences in the cardiac beta-adrenergic
receptor contractile response
Victoria Mcintosh
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Physiology Commons
Recommended Citation
Mcintosh, Victoria, "Sex differences in the cardiac beta-adrenergic receptor contractile response" (2012). Wayne State University
Dissertations. Paper 458.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

SEX DIFFERENCES IN THE CARDIAC β-ADRENERGIC RECEPTOR
CONTRACTILE RESPONSE
by
VICTORIA MCINTOSH
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2012
MAJOR: PHYSIOLOGY
Approved by:

Advisor

Date

© COPYRIGHT BY
VICTORIA MCINTOSH
2012
All Rights Reserved

DEDICATION
I dedicate this to my husband, Kiel McIntosh, who has been there for me every step of
the way since I decided to start the PhD program. He kept me grounded and was always willing
to buy me a cheeseburger when I had a rough day in lab. His belief in me is what kept me going.
I dedicate this to my daughter, Josephine McIntosh, who inspires me every day as I watch
her learn and grow, without bias or judgment. All of our sleepless nights together have given me
plenty of time to think about β-adrenergic receptors.
I dedicate this to my parents, Rick and Terrie Kramer, who encouraged me to take on
new challenges and push myself further than I ever thought I could. I am the person I am today
because of the support they gave me from the beginning, and I owe so much to them for that.

ii

ACKNOWLEDGEMENTS
I would like to begin by thanking Dr. Robert Lasley for his patience, support and
assistance in the development of this project. I am so grateful for the opportunity he gave me to
develop my own project, and that he was so enthusiastic and eager to explore something that his
lab had never done before. I could not have asked for a better mentor.
I would also like to thank my committee members, Dr. Roy McCauley, Dr. Patrick
Mueller, Dr. Karin Przyklenk and Dr. Javier Sala-Mercado, for their support and input over the
years.

I always looked forward to the chance to share my work with them, and received

invaluable input in every meeting we had.
I would like to extend a special thank you to Dr. Charu Chandrasekera, who trained me in
several of the techniques that were used in this project. Along with this training, I am very
grateful for the intellectual input she provided during those pesky troubleshooting stages.
I could not have gotten to this point without the assistance and support from the many
members of the Physiology Department, from students to faculty to staff. It meant so much to
have people there willing to assist me through this process in whatever capacity they could.
Finally, I would like to thank Dr. Jürgen Schnermann (NIDDK) for the generous gift of
A1AR knockout breeder mice, as well as Dr. Nabanita Datta for the use of her Real Time PCR
machine.

This work was supported by National Heart, Lung, and Blood Institute Grant,

R01HL066132 (Robert D. Lasley).

iii

TABLE OF CONTENTS
Dedication

ii

Acknowledgements

iii

List of Tables

ix

List of Figures

x

List of Abbreviations

xi

Chapter 1: Background

1

I. Introduction

1

II. β-Adrenergic Receptors in the Heart

2

III. Modulation of β-Adrenergic Receptor Function by Adenosine Receptors

4

IV. Sex Differences in the Cardiovascular System

5

V. Sex Differences in Cardiac Gene Expression

7

VI. Impact of Sex Steroid Hormone Withdrawal on Gene Expression and Cardiac
Function

8

VII. Sex Differences in β-Adrenergic Receptors

9

VIII. β-Adrenergic Receptors as Pharmaceutical Targets

11

IX. Summary and Hypothesis

12

Chapter 2: β-Adrenergic Contractile Response in Males, Intact Females and
Ovariectomized Females- Methods and Results

13

I. Rationale

13

II. Materials

13

III. Methods

14

A. Animal Model

14

B. Isolated Heart Preparation

14

C. β-Adrenergic Contractile Response Protocol

15

iv

D. Data and Statistical Analysis

15

IV. Results

16

A. Body and Tissue Weights

16

B. Baseline Hemodynamics

16

C. β-Adrenergic Contractile Responses

17

Chapter 3: Modulation of the β-Adrenergic Contractile Response by the A1
Adenosine Receptor in Males, Intact Females and Ovariectomized
Females- Methods and Results

19

I. Rationale

19

II. Materials

19

III. Methods

20

A. Animal Model

20

B. Isolated Heart Preparation

20

C. Protocol: Modulation of βR Contractile Response by A1 AR Activation

20

D. Protocol: Modulation of βR Contractile Response by A1AR Deletion

20

E. Protocol: Study of Adenosine Receptor Function using NECA

20

F. Data and Statistical Analysis

21

IV. Results

21

A. Modulation of βR Contractile Response by A1AR Activation

21

B. Modulation of βR Contractile Response by A1 AR Deletion

23

C. Chronotropic and Vascular Actions of AR

24

Chapter 4: Modulation of the G Protein Signaling Pathway in the Isolated HeartMethods and Results

26

I. Rationale

26

II. Materials

26

III. Methods

27
v

A. Animal Model

27

B. Isolated Heart Preparation

27

C. Forskolin, IBMX and CPT-cAMP Dose Response Protocols

27

D. Data and Statistical Analysis

27

IV. Results

27

A. Adenylyl Cyclase Activation in Males and Females

27

B. Phosphodiesterase Inhibition in Males and Females

28

C. Activation of cAMP-dependent Signaling in Males and Females

29

Chapter 5: β-Adrenergic and Adenosine Receptor Gene Expression in Males,
Intact Females and Ovariectomized Females- Methods and Results

31

I. Rationale

31

II. Materials

32

A. Ventricular Myocyte Isolation

32

B. RNA Isolation and PCR

32

III. Methods

32

A. Ventricular Myocyte Isolation

32

B. RNA Isolation and Real Time Quantitative PCR

33

D. Data and Statistical Analysis

34

IV. Results

34

A. Gene Expression in Ventricular Tissue

34

B. Gene Expression in Ventricular Myocytes

35

Chapter 6: Expression of Components of the G Protein Signaling Pathway
in Males and Females- Methods and Results

36

I. Rationale

36

II. Materials

36
vi

III. Methods

37

A. Animal Model and Ventricular Myocyte Isolation

37

B. Generation of Ventricular Myocyte Lysate

37

C. SDS-PAGE and Western Blotting

37

D. Data and Statistical Analysis

38

IV. Results

.38

Chapter 7: cAMP Accumulation following βR Stimulation in Male and Female MyocytesMethods and Results

42

I. Rationale

42

II. Materials

42

III. Methods

42

A. Animal Model and Ventricular Myocyte Isolation

42

B. Drug treatment, Lysis and ELISA

42

C. Data and Statistical Analysis

43

IV. Results

43

A. ISO Dose Response Studies

43

B. Effect of PDE Inhibition on cAMP Accumulation

44

Chapter 8: Signaling in Response to β-Adrenergic Receptor Stimulation
in Male and Female Myocytes- Methods and Results

46

I. Rationale

46

II. Materials

46

III. Methods

46

A. Animal Model and Ventricular Myocyte Isolation

46

B. Drug Treatment and Preparation of Myocyte Lysate

47

C. SDS PAGE and Western Blotting

47

vii

D. Data and Statistical Analysis

48

IV. Results

48

A. Troponin I Phosphorylation in Males and Females

48

B. Phospholamban Phosphorylation in Males and Females

48

Chapter 9: Discussion

50

I. Summary of Results

50

II. Sex Differences in the β-Adrenergic Contractile Response

50

III. Modulation of the βR Response by the A1 Adenosine Receptor

52

IV. G Protein Pathway Function in Male and Female Hearts

54

V. β-Adrenergic Receptor and Adenosine Receptor Gene Expression

56

VI. Expression of Components of the G Protein Pathway in Myocytes

58

VII. cAMP Accumulation Response to β-Adrenergic Receptor
Stimulation in Myocytes

59

VIII. Phosphorylation of TnI and PLB following β-Adrenergic Receptor
Stimulation in Myocytes

61

IX. Limitations

62

X. Summary, Conclusions and Future Directions

64

References

66

Abstract

81

Autobiographical Statement

83

viii

LIST OF TABLES
Table 1: Sex differences in the human cardiovascular system

6

Table 2: Body and tissue weights in wild type mice

16

Table 3: Baseline hemodynamics in wild type mice

16

Table 4: Hemodynamic responses to 200 nM CCPA in wild type mice

21

Table 5: Primary antibody dilutions for western blotting

38

ix

LIST OF FIGURES
Figure 1: β-Adrenergic receptor signaling pathway

3

Figure 2: Experiment record

15

Figure 3: Hemodynamic responses to ISO

17

Figure 4: Hemodynamic responses to ISO with CCPA pre-treatment

22

Figure 5: Hemodynamic responses to ISO in A1 ARKO hearts

23

Figure 6: Hemodynamic responses to NECA

24

Figure 7: Hemodynamic responses to forskolin

28

Figure 8: Hemodynamic responses to IBMX

29

Figure 9: Hemodynamic responses to CPT-cAMP

30

Figure 10: Expression of β-adrenergic receptors and adenosine receptors
in ventricular tissue

34

Figure 11: Expression of β-adrenergic receptors and adenosine receptors
in ventricular myocytes

35

Figure 12: Gsα protein expression in myocytes

39

Figure 13: Gi-2α protein expression in myocytes

39

Figure 14: Adenylyl cyclase V/VI expression in myocytes

40

Figure 15: Phosphodiesterase 4D expression in myocytes

40

Figure 16: Protein Phosphatase 1 expression in myocytes

41

Figure 17: Protein Phosphatase 2A expression in myocytes

41

Figure 18: cAMP accumulation following ISO treatment in myocytes

44

Figure 19: cAMP accumulation following ISO treatment with and
without rolipram in myocytes

45

Figure 20: Phosphorylation of troponin I following ISO treatment in myocytes

48

Figure 21: Phosphorylation of phospholamban following ISO treatment in myocytes

49

x

LIST OF ABBREVIATIONS
A1AR- A1 adenosine receptor
A1ARKO- A1 adenosine receptor knock out
A2aAR- A2a adenosine receptor
A2bAR- A2b adenosine receptor
A3AR- A3 adenosine receptor
AC- adenylyl cyclase
AKAP- a kinase anchoring protein
β1R- β1 adrenergic receptor
β2R- β2 adrenergic receptor
bpm- beats per minute
Cav1.2- alpha 1c subunit of L type calcium channel
CCPA- 2-chloro-N(6)-cyclopentyladenosine
CF- coronary flow
CPP- coronary perfusion pressure
CPT-cAMP- 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic monophosphate
CVD- cardiovascular disease
DMSO- dimethyl sulfoxide
ECL- enhanced chemiluminescence
ELISA- enzyme-linked immunosorbent assay
FSK- forskolin
GPCR- G-protein couple receptor
GPR30- G-protein coupled receptor 30 (i.e. G protein-coupled estrogen receptor)
HR- heart rate
xi

HRP- horseradish peroxidase
IBMX- 1-methyl-3-isobutylxanthine
ISO- isoproterenol
KHB- Krebs-Henseleit buffer
KO- knockout
LTCC- L-type calcium channel
LV- left ventricle
LVSP- left ventricular systolic pressure
NCX- sodium-calcium exchanger
NECA- 5′-(N-ethylcarboxamido)adenosine
OvX- ovariectomy
PBS- phosphate buffered saline
PDE- phosphodiesterase
PKA- protein kinase A
PLB- phospholamban
PP1- protein phosphatase 1
PP2A- protein phosphatase 2A
pPLB- phospho-phospholamban
pTnI- phospho-troponin I
RyR- ryanodine receptor
SERCA- sarcoplasmic/endoplasmic reticulum calcium ATPase
SR- sarcoplasmic reticulum
TBS- Tris buffered saline
TBST- Tris buffered saline with Tween-20
xii

TnI- troponin I
WT- wild type

xiii

1
CHAPTER 1: Background
I. Introduction
It is well documented that sex differences exist in the susceptibility to cardiovascular
disease. Prior to menopause, the incidence of cardiovascular disease is lower in age-matched
females than in males (Barrett-Connor et al. 1997; Crabbe et al. 2003; Hayward et al. 2001).
Following completion of menopause, the risk of developing cardiovascular disease in females
increases dramatically (Hayward et al. 2001).

Additionally, it has been demonstrated that

females suffering from cardiovascular disease show reduced responsiveness to typical
interventions than males, and greater likelihood of developing heart failure after suffering a
myocardial infarction (Xhyheri et al. 2010; Huxley 2007). A role for sex steroid hormones in
modulating cardiovascular function has been demonstrated in several species (including humans),
in both normal and pathological states.

In spite of these observations, the majority of

cardiovascular research is still performed only in males (Leinwand 2003).
β-adrenergic receptors are central mediators of cardiovascular function, making them key
pharmaceutical targets in the treatment of cardiovascular disease (CVD).

It has been

demonstrated in ventricular myocytes and left atrial tissue that males show enhanced contractile
responsiveness to β-adrenergic receptor stimulation as compared to females (Curl et al. 2001;
Schwertz et al. 1999; Vizgirda et al. 2002). In contrast, other groups in muscle strip models have
not seen these differences (Chu et al. 2005; Monasky et al. 2008). However, whether sex
differences exist in β-adrenergic responsiveness in intact myocardium, as well what the potential
mechanisms for these differences could be has not been fully elucidated. Therefore, the first aim
of this study was to determine the contractile response to β-adrenergic receptor stimulation in the
isolated perfused heart using age-matched male and female mice, and address potential
mechanisms for any observed sex differences in the intact heart. The second aim of this study
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was to address potential mechanisms for sex differences in the β-adrenergic contractile response
using adult ventricular myocytes. Uncovering the mechanism for sex differences in the βadrenergic receptor contractile response may enable enhanced, sex-specific pharmaceutical
treatments for cardiovascular disease.
II. β-Adrenergic Receptors in the Heart
The β-adrenergic receptors belong to the family of 7 transmembrane G protein-coupled
receptors (GPCR), of which there are three subtypes: β1, β2 and β3. The β-adrenergic receptors
are highly conserved across species, from mouse to human. Stimulation of cardiac β-adrenergic
receptors by norepinephrine (released by sympathetic nerve terminals) results in an increased
heart rate (positive chronotropy), increased force of contraction (positive inotropy) and increased
rate of relaxation (positive lusitropy). The positive chronotropic, inotropic, and lusitropic effects
of β-adrenergic receptor stimulation are mediated primarily by the β1 adrenergic receptor and to
lesser extent the β2 adrenergic receptor (Rohrer et al. 1999; Chrusinski et al. 1999).
The β1-adrenergic receptor (β1R) is coupled to Gsα protein, and stimulates increases in
contractility via the adenylyl cyclase-cAMP-protein kinase A signaling pathway.

The β2-

adrenergic receptor (β2R) is expressed in significantly lower levels than the β1R. The ratio of
β1R to β2R is approximately 70-80:20-30 β1R to β2R in human ventricle (Brodde 1991), and
approximately 75:25 in mouse myocytes (Zhu et al. 2005). The β2R can couple to both Gsα and
Giα proteins on ventricular myocytes (Xaio et al. 1995), and can therefore stimulate or inhibit
cAMP-mediated signaling depending on the coupling status of the receptor.
The positive lusitropic and intropic states of the myocyte elicited by β-adrenergic
receptor stimulation are ultimately determined by the degree of phosphorylation of troponin I
(TnI), phospholamban (PLB), the ryanodine receptor (RyR) and the L-type calcium channel
(Xiang et al. 2003). Phosphorylation of TnI at serine 23/24 by cAMP-dependent protein kinase
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(PKA) results in a reduced affinity of the troponin complex for calcium, enhancing the rate of
relaxation

of

the

myocyte

(Pi

et

al.

2002).

PLB

negatively

regulates

the

sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), the calcium reuptake channel
on the SR. Phosphorylation of PLB at residue serine 16 reduces its inhibition of SERCA,
allowing enhanced calcium uptake into the sarcoplasmic reticulum (SR) and enabling enhanced
rates of myocyte relaxation (Chu et al. 2000). The RyR is the calcium release channel on the
sarcoplasmic reticulum. It has been speculated that phosphorylation of the RyR at serine 2808
by PKA increases the probability of the RyR being open (Shan et al. 2010), enabling enhanced
calcium availability for contraction. The L-type calcium channel on the sarcolemma allows
calcium movement into the cell during the myocyte action potential, resulting in calciuminduced release of SR calcium.

Phosphorylation of this channel (Hulme et al. 2006) also

increases the amount of calcium than may enter the cell. This signaling pathway is shown in
Figure 1.
β2R

β1R
Adenylyl
Cyclase

-

+

Gsα

+
ATP

A1AR

cAMP

Giα

Giα

Gsα

PDE
AMP

PKA
LTCC

TnI
PLB

PP1, PP2A

RyR

Figure 1- β-adrenergic receptor signaling pathway. β1R- β1-adrenergic receptor, β2R- β2adrenergic receptor, A1AR- A1 adenosine receptor, PDE- phosphodiesterase, PKA- protein
kinase a, TnI- troponin I, PLB- Phospholamban, RyR- ryanodine receptor, LTCC- L-type
calcium channel, PP1- protein phosphatase 1, PP2A- protein phosphatase 2A.
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Note in Figure 1 that cAMP levels in the cell are modulated by 3’,5’-cyclic nucleotide
phosphodiesterase (PDE) enzymes, which convert cAMP to 5’-AMP (as well as cGMP to 5’GMP).

Phosphodiesterases regulate basal cAMP levels as well as cAMP levels during β-

adrenergic receptor stimulation. There are 11 known families of PDEs, and at least four cAMPhydrolyzing PDE families have been shown to be expressed in the heart: PDE1, PDE2, PDE3
and PDE4 (Pang 1992). PDE4 is phosphorylated and activated by PKA, and appears to be the
primary isoform involved in modulation of the β-adrenergic contractile response (De Arcangelis
et al. 2008; Mongillo et al. 2004; Perry et al. 2002; Richter et al. 2008; Xiang et al. 2005).
Also involved in the modulation of β-adrenergic receptor signaling are protein
phosphatases, enzymes that remove phosphate groups from the aforementioned target proteins.
Protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) are both serine/threonine
phosphatases that account for more than 90% of dephosphorylation reactions in mammalian cells
(Herzig et al. 2000).

Both forms of protein phosphatases have been shown to modulate

phosphorylation states of phospholamban, troponin I, etc (Liu et al. 2002; MacDougall et al.
1991). βR stimulation results in reduced protein phosphatase 1 activity, via activation of protein
phosphatase inhibitor-1 (Neumann et al. 1991). Protein phosphatases and phosphodiesterases are
both part of an intrinsic regulatory system in myocytes, preventing extreme contractile responses
elicited by β-adrenergic receptor activation.
III. Modulation of β-Adrenergic Receptor Function by Adenosine Receptors
Adenosine is an autocoid which is produced through the hydrolysis of 5’AMP by 5’nucleotidase.

Levels of adenosine consequently increase during conditions in which ATP

breakdown is increased, such as during β-adrenergic receptor stimulation (Manfredi et al. 1982;
Saito et al. 1980; Wiedmeier et al. 1977). Adenosine exerts its effects through binding to G
protein-coupled adenosine receptors (AR), which play roles in both modulation of normal
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cardiovascular function and promotion of cardioprotection. There is evidence for the expression
of all four adenosine receptors (A1, A2a, A2b and A3) in the heart, though only the expression of
the A1 adenosine receptor (A1AR) in the cardiac myocyte has been confirmed using radioligand
binding (Martens et al. 1988). Activation of the A1 AR on sinoatrial and atrioventricular nodal
tissue has a dramatic negative chronotropic effect. Additionally, activation of both A2aAR and
A2bAR on vascular tissue results in potent vasodilation. Both A1AR and A2aAR have a high
affinity for the endogenous ligand adenosine, while the A2bAR has a low affinity for adenosine.
The A1AR couples to Giα protein and limits the positive inotropic effects of β-adrenergic
receptor stimulation (the so-called “anti-adrenergic effect”). Multiple models have demonstrated
that pre-treatment with an A1AR agonist results in reduced contractile responses to βR agonist
treatment (Belardinelli et al. 1983; Brown et al. 1990; Perlini et al. 1998; Richardt et al. 1989).
Additionally, pharmacological inhibition of the A1AR has been shown to potentiate the
contractile effect of βR stimulation, suggesting there is a role for endogenous adenosine in
regulating the normal β-adrenergic contractile response (Dobson et al. 1986; Dobson et al. 1996).
While the A2aAR does not alter β-adrenergic receptor function directly, both pharmacological
inhibition and genetic deletion of the A2aAR has been shown to enhance the anti-adrenergic
effect of the A1 adenosine receptor in the isolated heart (Chandrasekera et al. 2010; Norton et al.
1999).
IV. Sex Differences in the Cardiovascular System
Multiple investigators have demonstrated that sex differences exist both in the normal
cardiovascular system and in susceptibility to cardiovascular disease. Some of these differences
are shown in Table 1 (summarized from Virginia Huxley Refresher Course, Advances in
Physiology Education, 2007).
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Table 1- Sex differences in the human cardiovascular system
Sex Difference
Anatomy
Greater ventricular mass in males
Greater major vessel size in males
Electrophysiology
Higher heart rate in females than males
Longer QT interval in females than males
Lower expression of some subclasses of potassium channels
involved in repolarization in females
Autonomic Control
Response to cardiovascular stress: males tend to increase total
peripheral resistance and females tend to increase heart rate
Lower sympathetic activity, enhanced parasympathetic activity in
females; higher plasma norepinephrine in older males
Pathology
Susceptibility to hypertension greater in males
Reduced susceptibility to heart failure in general population in
females
Susceptibility to heart failure following MI greater in females
Acute myocardial infarct symptoms differ between males and
females

Reference
De Simone et al. 1991;
Hammond et al. 1988;
Levy et al. 1987
Vasan et al. 1997
Umentani et al. 1998
Surawicz et al. 2003
Gaborit et al. 2010

Barnett et al. 1999
Geelen et al. 2002

Messerli et al. 1987
Gottdiener et al. 2000
Tofler et al. 1987
Chen et al. 2005

As shown in Table 1, it is well-documented that sex differences are present in multiple
cells types in the human heart, including conductive tissue, vascular tissue, and myocytes. Sex
differences in the cardiovascular system have also been demonstrated in other species (canine,
rabbit, guinea pig, rat mouse, etc).
The sex differences of interest to this project relate to primarily to ventricular myocytes
and calcium regulation. Several groups have demonstrated in rodent models that females display
greater basal L-type calcium channel current (Vizgirda et al. 2002; Xiao et al. 2006) though
others have shown no such differences (Kennedy et al. 2003; Sun et al. 2006). Additionally, it
has been demonstrated in both myocyte (Curl et al. 2001; Farrell et al. 2010; Petre et al. 2007;
Wasserstrom et al. 2008) and papillary muscle (Curl et al. 2008; Leblanc et al. 1998) that males
show greater basal contractile amplitude than females. Farrell and colleagues recently published
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that sex differences exist in excitation-contraction coupling gain (i.e. calcium flux per unit ICaL),
with females showing significantly lower gain as compared to males (Farrell et al. 2010). If
these differences exist in the basal state, there are likely ramifications in terms of both enhanced
stimulation by βR as well as under pathological conditions.
V. Sex Differences in Cardiac Gene Expression
The role of sex steroid hormones in modulating gene expression is commonly addressed
as a potential mechanism for the presence of sex differences exist in the cardiovascular system.
The classical function of both estrogen and testosterone is to modulate gene transcription,
accomplished through binding to their nuclear receptors (estrogen receptor alpha and beta, and
androgen receptor, respectively). There is evidence for the expression of both nuclear estrogen
receptor subtypes (Grohé et al. 1997), as well as the nuclear androgen receptor (Marsh et al.
1998) in cardiac myocytes. Expression of these receptors in vascular tissue has also been
demonstrated (Barton et al. 2007; Hodges et al. 2000; Liu et al. 2005).
Sex differences in the expression of many genes coding for proteins involved in
cardiovascular function have been demonstrated. For example, Gaborit and colleagues found
that non-diseased human female hearts show reduced gene and protein expression of many K+
channel subunits (Gaborit et al. 2010), and this has also been shown in murine myocardium
(Saito et al. 2009). Isensee and colleagues performed a thorough analysis of sexually dimorphic
gene expression in both young and aged mouse myocardium, as well as human myocardium, and
found numerous genes involved in cellular processes such as signaling, growth, regulation, stress
responses, etc. to be different in expression between male and female (Isensee et al. 2008). Chu
and colleagues found gene and protein expression of the sodium-calcium exchanger (NCX) and
ryanodine receptor to be higher in females than males, and also found that Cav1.2 (a subunit of
the L-type calcium channel) protein expression was higher in females (though Cav1.2 gene
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expression was higher in males) (Chu et al. 2005).
Along with modulating gene expression, sex steroids have also been shown to act on a
more acute time-scale by activating cellular signaling cascades. There are reports that estrogen
can bind to both translocated nuclear estrogen receptors and the G protein-coupled receptor
GPR30 at the plasma membrane and activate the phosphoinositide 3-kinase-Akt signaling
cascade (Revankar et al. 2005), a signaling pathway implicated in cardioprotection.

Both

estrogen and testosterone have been shown to alter intracellular calcium acutely, independent of
effects on transcription (Buitrago et al. 2000; Er et al. 2007). Estrogen and testosterone also
have effects on vascular tone, presumably non-genomic and more likely related to these changes
in intracellular calcium.
VI. Impact of Sex Steroid Hormone Withdrawal on Gene Expression and Cardiac Function
The increased risk of developing cardiovascular disease following menopause provides
more evidence for the role played by ovarian hormones in the cardiovascular system. The
impact of ovarian hormones (estrogen and progesterone) on cardiovascular function is
commonly addressed using the ovariectomy model. Ovarian hormone withdrawal in females has
been shown to change the expression of L-type calcium channel and the sodium-calcium
exchanger (Chu et al. 2006).

Additionally, functional consequences of ovarian hormone

withdrawal have been demonstrated. Ma and colleagues showed that rat ventricular myocytes
from ovariectomized females display greater resting calcium levels and greater amplitudes of
calcium transients than myocytes from intact females (Ma et al. 2009). Greater calcium channel
activity has been observed in ovariectomized as compared to intact female myocytes, as well as
greater basal PKA activity in ovariectomized female myocytes (Kam et al. 2005). Patterson and
colleagues documented increased LTCC density in rabbit myocardium from ovariectomized
females (Patterson et al. 1998). Reduced peak shortening and velocities of shortening and
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relenghtening were observed in myocytes from ovariectomized female mice as compared to
intact female mice (Ren et al. 2003).
Testosterone withdrawal via castration has also been shown to change the expression of
genes involved in calcium regulation: Golden and colleagues demonstrated that cardiac tissue
from castrated males expressed lower levels of the L-type calcium channel genes and
dramatically lower levels of NCX than intact males (Golden et al. 2002). In a subsequent study
they demonstrated that testosterone withdrawal increased the time to peak shortening and
relengthening in myocytes (Golden et al. 2003).
VII. Sex Differences in β-Adrenergic Receptors
As noted previously, multiple reports suggest that myocytes from females display
reduced β-adrenergic contractile responsiveness to the non-selective β-adrenergic receptor
agonist isoproterenol (ISO) as compared to myocytes from males (Curl et al. 2001; Vizgirda et al.
2002), a finding which was also demonstrated in left atrial tissue (Schwertz et al. 1999). In
contrast, other groups using muscle strip models have shown no such differences (Chu et al.
2005; Monasky et al. 2008). Additional inconsistencies exist in the literature regarding the
mechanism for sex differences in the β-adrenergic contractile response. Some have proposed
that females show reduced expression of βR (Vizgirda et al. 2002), and that sex differences exist
in calcium regulation upon βR stimulation (Chen et al. 2003; Curl et al. 2001; Curl et al. 2008;
Vizgirda et al. 2002). For example, Chen and colleagues have demonstrated that sex differences
in ischemia/reperfusion injury only manifest themselves if hearts are also exposed to
isoproterenol, with females showing less injury than males in this condition (Chen et al. 2003).
However, a thorough investigation into cardiac β-adrenergic receptor function and signaling in
both males and females has not been conducted.
Multiple groups have shown that ovarian hormone withdrawal (via ovariectomy) results
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in increased expression of the β1R in rat cardiac tissue (Chu et al. 2006; Thawornkaiwong et al.
2003). Treatment of ovariectomized rats with estrogen and progesterone has been shown to
increase β-adrenergic receptor density but decrease receptor binding in cardiac tissue
(Klangkalya et al. 1988). In spite of β-adrenergic receptor upregulation in ventricular tissue, Chu
and colleagues saw no functional difference in the contractile response to receptor stimulation in
right ventricular papillary muscle strips between intact and ovariectomized females (Chu et al.
2006). This has also been observed in rabbit papillary muscle (Patterson et al. 1998). In contrast,
Kam and colleagues found that ovariectomized rat female myocytes displayed enhanced PKA
and L-type calcium channel activity responses to isoprenaline treatment as compared to intact
female myocytes. They also found enhanced contractile responses to isoprenaline in an isolated
rat heart model in ovariectomized as compared to intact females (Kam et al. 2005).
Sex differences in βR signaling, or modulation of βR signaling by phosphodiesterases or
protein phosphatases, has not been addressed in the literature. While multiple groups have
demonstrated that contractile differences exist in male and female ventricular myocytes
stimulated with isoproterenol, there are no known studies that compared the βR signaling
cascade in males and females.
Sex Differences in Adenosine Receptors
As previously mentioned, A1 adenosine receptors exert a potent anti-adrenergic effect on
the contractile response to βR stimulation. The role of A1AR in differentially modulating the βR
response in males and females has never been investigated. Furthermore, little research has been
done to investigate sex differences in adenosine receptors. One report indicates that there are no
gender differences in A1AR and A3AR gene expression in mouse hippocampus (von Armin et al.
2002). Ovariectomy and estrogen replacement has been shown to modulate adenosine receptor
gene expression in both rat and mouse brain (Ribeiro et al. 2009; Rose’Meyer et al. 2003).
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However, there are no reports on sex differences in cardiac adenosine receptor expression.
Additionally, little research has been done on sex differences in cardiac adenosine receptor
function. In two reports, Yang and colleagues noted that genetic deletion of the A1AR in females
had little effect on heart rate, whereas males showed increases in heart rate following A1 AR
deletion (Yang et al. 2009; Yang et al. 2007).
VIII. β-Adrenergic Receptors as Pharmaceutical Targets
The genome codes for approximately 350 G protein-coupled receptors that detect
hormones, growth factors and other endogenous ligands (Vassilatis et al. 2003), and these
receptors are the targets of approximately 30% of current pharmaceutical treatments (Overington
et al. 2006). Included in these targets are the β-adrenergic receptors, as β- adrenergic receptor
antagonists (“beta-blockers”) are commonly prescribed to prevent or treat hypertension, stroke,
and other cardiovascular conditions.

Interestingly, Lujan and colleagues demonstrated that

females have a greater ventricular arrhythmia threshold (VAT) than males during coronary artery
occlusion in conscious rats, and that βR blockade only prolonged VAT in males (Lujan et al.
2008). Additionally, while there were no differences in incidence of ventricular tachycardia
(VT) following coronary artery occlusion and reperfusion between males and females, βR
blockade reduced the incidence of VT only in females (Lujan et al. 2007).
Although multiple groups have shown that sex differences exist in β-adrenergic receptor
expression and function, and that changes in βR expression and function occur following ovarian
hormone withdrawal, there are currently no guidelines for treating males and females with CVD
differently using β-adrenergic receptor blockers. Interestingly, it has been demonstrated that
females show greater morbidity and mortality following diagnosis of cardiovascular disease than
males, suggesting that there is precedence for differentially treating the sexes (Kannel et al.
1995; Tofler et al. 1987). Elucidation of the mechanism for sex differences in β-adrenergic
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receptor signaling may enable the development of enhanced, specialized pharmaceutical
treatments for cardiovascular disease in males and females, as well as pre- versus postmenopausal females.
IX. Summary and Hypothesis
Males and females display numerous differences in cardiovascular function, including at
the level of the myocardium.

While this has been well-documented, the majority of

cardiovascular research is still performed only in males. Sex differences in the contractile
response to stimulation of a key receptor family in the myocardium, the β-adrenergic receptors,
have been demonstrated in ventricular myocytes. However, this has not been shown in an intact
heart, nor has a mechanism for these differences been elucidated. Therefore, the following is the
primary hypothesis of this dissertation:
Hypothesis 1: Females show reduced β-adrenergic contractile responsiveness in the
isolated perfused heart.
While basic mechanisms such as calcium regulation following βR stimulation have been
considered to address reduced βR responsiveness in females, a robust analysis of βR signaling in
myocardial or ventricular myocyte tissue has not been performed to date.

A secondary

hypothesis of this dissertation was established to address this deficiency:
Hypothesis 2: Females show altered function or expression of components of the βadrenergic receptor signaling pathway relative to males, which contributes to their reduced
contractile responsiveness to β-adrenergic receptor stimulation.
The role of ovarian hormones in generating an altered β-adrenergic response was
considered as well, using ovariectomized female mice.
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Chapter 2: β-Adrenergic Contractile Response in Males, Intact Females and
Ovariectomized Females- Methods and Results
I. Rationale
The first hypothesis of this study was that females would show a reduced contractile
response to βR stimulation as compared to males. This prediction was based on a thorough
survey of the literature, in which the majority of investigators have documented this sex
difference in myocytes. However, isolated myocyte studies are limited, as cells are typically
maintained at un-physiologically low temperatures and paced at extremely low rates for these
studies. This question had not been addressed in a more physiological model such as the intact
heart, maintained at 37°C and beating at 420 beats per minute.
These studies were also performed in hearts from female mice that were ovariectomized.
This was done in order to determine if ovarian hormones play a role in generating sex differences
in the β-adrenergic contractile response.

Ovarian hormone withdrawal, such as that which

occurs during menopause, has important physiological consequences which were discussed in
the Background. These studies could provide insight into the role of ovarian hormones in
modulation of the β-adrenergic contractile response. A thorough survey of the literature was
performed on this topic, and it was predicted that the contractile response would be enhanced in
ovariectomized mice as compared to intact female mice.
II. Materials
Deionized, distilled water was purchased from Lonza (Basel, Switzerland). Isoproterenol
(ISO), NaCl, KCl, KH2PO4, MgSO4, NaHCO3, CaCl2, Glucose, Sodium Pyruvate and EDTA were
purchased from Sigma-Aldrich, Inc (St Louis, MO). ISO was prepared as a 10 mM stock
solution in phosphate buffered saline with 0.1% sodium metabisulfite.
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III. Methods
A. Animal Model
The animals in this study were maintained and used in accordance with guidelines in the
Guide for the Care and Use of Laboratory Animals (NIH Publication, No 85-23, Revised 1996)
and evaluated and approved according to the guidelines of the Institutional Animal Care and Use
Committee of the Wayne State University School of Medicine. Ten- to twelve-week old wildtype C57BL/6 male and female mice were purchased from Jackson Laboratories (Bar Harbor,
ME).

Additionally, females that were ovariectomized (OvX) at five weeks of age were

purchased from Jackson Laboratories, and allowed 5-7 weeks for estrogen withdrawal to occur
prior to study.

Estrogen withdrawal was confirmed by comparing the uterine weight/body

weight ratio in intact females and ovariectomized females. Estrus cycle was not monitored in
intact females.
B. Isolated Heart Preparation
Hearts were excised from anesthetized (sodium pentobarbital, 60 mg/kg) and heparinized
(500 units) mice, placed in ice-cold saline and mounted on a perfusion apparatus. Hearts were
perfused at 70 mm Hg with standard Krebs-Henseleit Buffer (KHB)- in mM: NaCl 116, KCl 4.7,
KH2PO4 1.2, MgSO4 1.2, NaHCO3 24.5, CaCl2 2.0, glucose 11, sodium pyruvate 2.0, EDTA
0.05. KHB was filtered using a 0.22 μm in-line filter. The pH of the KHB was maintained in at
7.4 by gassing with 95% O2 and 5% CO2. Temperature was maintained at 37°C with constanttemperature reservoirs, and by partially submerging the heart into a 37°C water-jacketed
chamber filled with KHB. Hearts were paced at 420 beats per minute (bpm) via pacing wires
inserted into the right ventricle, and a fluid-filled balloon was inserted into the left ventricle (LV)
across the mitral valve and connected to a pressure transducer, permitting continuous
measurement of LV pressure. The fluid-filled balloon was inflated to record a LV diastolic
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pressure of 5-8 mmHg. Ventricular function (LV pressure, +dP/dt and –dP/dt), heart rate (HR),
coronary flow (CF), and coronary perfusion pressure (CPP) were continuously monitored and
recorded throughout the experiments (shown in Figure 2, below). All data were collected and
analyzed using PowerLab data acquisition systems and LabChart Software for Windows (AD
Instruments, Inc., Colorado Springs, CO).
Figure 2- LabChart experiment record,
baseline tracing. LVP- left ventricular
pressure; CF- coronary flow; CPPcoronary perfusion pressure.

C. β-Adrenergic Contractile Response Protocol
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the
experimental protocol. The working dilution of ISO was added directly to the perfusion buffer.
Each heart was administered three doses of ISO (1, 2 and 10 nM), and maintained at a constant
coronary perfusion pressure of 70 mmHg by increasing coronary flow as vasodilation occurred.
Steady-state responses to ISO were assessed after approximately two minutes infusion of each
dose.
D. Data and Statistical Analysis
Data were analyzed with GraphPad Prism software and presented as means ± SE. T-tests,
one-way ANOVAs and two-way repeated measures ANOVAs were performed when appropriate.
Post-hoc analysis using the Bonferroni’s method was performed when necessary. Statistically
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significant differences in the values were taken at p < 0.05.
IV. Results
A. Body and Tissue Weights
Intact females weighed less than age-matched males, and absolute ventricular weight was
also significantly lower in intact females as compared to males (Table 2, below; weights taken
from multiple series of experiments). However, the ventricular weight/body weight ratio was no
different between males and females.
Table 2- Body and tissue weights in wild type mice
Males
Intact
Females
OvX
Females

Body Wt. (g)

Ventricular Wt.
(mg)

Ventricular Wt./Body
Wt. (mg/g)

Uterine Wt/Body
Wt. (mg/g)

n

28 ± 1

132 ± 2

4.8 ± 0.1

-

20

20 ± 1*

103 ± 4*

5.2 ± 0.2

4.0 ± 0.5

17

22 ± 1*,†

107 ± 4*

5.0 ± 0.2

0.4 ± 0.1†

14

Data are means ± SE, analyzed using one-way ANOVA or t-test. *p<0.05 intact female vs. male,
†p<0.05 OvX female vs. intact female

Body weight was significantly increased in ovariectomized females relative to intact
females, with no difference in ventricular weight or ventricular weight/body weight ratio.
Uterine weight/body weight ratio was significantly reduced in OvX females, confirming ovarian
hormone withdrawal.
B. Baseline Hemodynamics
There were no differences in the baseline contractile parameters between males and intact
females (Table 3; baseline values averaged from several series of experiments). Coronary flow
normalized to ventricular weight was significantly higher in intact females than in males.
Table 3- Baseline hemodynamics in wild type mice
LVSP (mmHg)
Male
Intact Female
OvX Female

+dP/dt
(mmHg/sec)

-dP/dt
(mmHg/sec)

Coronary Flow
(mL/min/g)

n

100 ± 2
4014 ± 104
-2304 ± 57
19 ± 1
30
103 ± 2
4150 ± 163
-2426 ± 88
23 ± 1*
27
90 ± 3*,†
3334 ± 138*,†
-2039 ± 88†
22 ± 1
14
Data are means ± SE, analyzed using one-way ANOVA. LVSP- left ventricular systolic pressure.
*p<0.05 intact, OvX female vs. male, †p<0.05 OvX female vs. intact female
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Ovariectomized females had a significantly lower baseline LVSP, +dP/dt and -dP/dt than
intact females. LVSP and +dP/dt in OvX females were also significantly lower than in males.
However, ovariectomy did not alter coronary flow in females.
C. β-Adrenergic Contractile Responses
The β-adrenergic contractile response to ISO (1, 2 and 10 nM) in hearts from males,
intact females and ovariectomized females is presented in Figure 3A-D. While LVSP increased
upon ISO stimulation, slight decreases were seen in LV diastolic pressure.

Figure 3- Hemodynamic responses to ISO. Presented as % change from pre-ISO baseline in
male (n=10), intact female (n=7) and ovariectomized female (n=8) mouse hearts (A- LVSP, B+dP/dt, C- -dP/dt and D- coronary flow). Data are means ± SE, analyzed using two-way
ANOVA with repeated measures. *p<0.05 between groups (male, intact female, OvX female)
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Males showed a greater contractile response to ISO than did intact and ovariectomized
females (in terms of LVSP, +dP/dt and –dP/dt). For example, at 1 nM ISO the percent increases
in LVSP for males and intact females were 64 ± 7 and 39 ± 5%; for +dP/dt, 101 ± 15 and 54 ±
8%, and for –dP/dt, 122 ± 14 and 67 ± 10%, respectively. At 1 nM ISO the percent increase in
LVSP for ovariectomized females was 45 ± 5%, for +dP/dt, 67 ± 7%, and for –dP/dt, 80 ± 12%.
Along with an increase in contractility, administration of ISO resulted in coronary
dilation. Percent changes were calculated using raw coronary flow data, not normalized to
ventricular weight, which was not different between the groups (in mL/min, males- 2.4 ± 0.1,
intact females- 2.1 ± 0.2; OvX females- 2.3 ± 0.2). There were no differences between the
groups in their dilatory response to ISO (p=0.0620). Percent increases from baseline coronary
flow of 39 ± 5% in males, 25 ± 3% in intact females and 23 ± 4% in ovariectomized females
were observed at 2 nM ISO.
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Chapter 3: Modulation of the β-Adrenergic Contractile Response by the A1 Adenosine
Receptor in Males, Intact Females and Ovariectomized Females- Methods and Results
I. Rationale
Females displayed a reduced contractile response to β-adrenergic receptor stimulation as
compared to males in the isolated heart. As mentioned in the Background, the A1 adenosine
receptor (A1AR) is known to negatively modulate the βR contractile response. To test the theory
that sex differences exist in the A1AR anti-adrenergic effect, contributing sex differences in the
βR response, two series of experiments were performed. First, activation of the A1AR using
selective agonist CCPA was performed prior to ISO administration to blunt the normal βadrenergic contractile response. While ovariectomy was not found to alter the βR contractile
response, the A1AR anti-adrenergic effect was tested in OvX mice as well. Secondly, the role of
endogenous adenosine in modulating the βR response in both males and females was
investigated using A1ARKO mice. Due to limitations in number of available A1 ARKO mice,
and since there were no differences in the normal βR response between intact and OvX females,
these studies were not performed in ovariectomized A1ARKO mice.
Interesting results in the aforementioned studies led to the development of an additional
series of experiments. A1AR, A2aAR and A2bAR function in the isolated heart was investigated
using the non-selective AR agonist 5’-(N-Ethylcarboxamideo)adenosine.

This experiment

enabled an analysis of A1AR-mediated reductions in heart rate, as well as A2aAR and A2bARmediated coronary vasodilation in a single heart.
II. Materials
KHB and ISO were purchased and prepared as described in Chapter 2.
Ethylcarboxamideo)adenosine

(NECA)

and

2-chloro-N6-cyclopentyl-adenosine

5’-(N(CCPA)

(Sigma-Aldrich Inc, St Louis, MO) were prepared as 10 mM stocks in dimethyl sulfoxide
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(DMSO) and diluted as necessary. DMSO concentration in the perfusate remained <0.1%.
III. Methods
A. Animal Model
Wild type male, intact female and ovariectomized female mice were obtained and
handled as described in Chapter 2. Global constitutive A1AR homozygous knockout (A1ARKO)
male and female mice were obtained from A1 AR heterozygous knockout breeders (C57BL/6
background) provided by Jürgen Schnermann (NIDDK), and genotype was confirmed by tailsnip PCR (performed by Transnetyx, Memphis TN).
B. Isolated Heart Preparation
Performed as described in Chapter 2, with the exception that pacing wires were not
inserted into ventricular tissue in the NECA dose response study.
C. Protocol: Modulation of βR Contractile Response by A1AR Activation
Hearts from wild type males, intact females and ovariectomized females were allowed to
equilibrate for approximately 20 minutes prior to initiation of the experimental protocols. Both
CCPA and ISO were added directly to the perfusion buffer. Hearts were infused with 200 nM
CCPA (an A1 AR agonist) for five minutes prior to and during ISO exposure. The ISO dose
response protocol was performed as described in Chapter 2.
D. Protocol: Modulation of βR Contractile Response by A1AR Deletion
The ISO dose response protocol was performed as described in Chapter 2, using male and
female A1ARKOs.
E. Protocol: Study of Adenosine Receptor Function using NECA
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the
experimental protocol. NECA dose response studies were performed at constant coronary flow
in unpaced hearts, to monitor changes in coronary perfusion pressure as well as heart rate.
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Hearts were infused with the following doses of NECA (in nM: 0.5, 1, 5, 10, 50, 100, 500, and
1000), and steady-state responses to each dose were assessed after two minutes of infusion.
F. Data and Statistical Analysis
Performed as described in Chapter 2, using a two-way ANOVA with repeated measures.
III. Results
A. Modulation of βR Contractile Response by A1AR Activation
Treatment with 200 nM CCPA significantly increased LVSP, +dP/dt and –dP/dt in both
males and intact females, with no effect on these parameters in ovariectomized females, shown
in Table 4. Coronary flow was increased following CCPA treatment in all three groups.
Table 4- Hemodynamic responses to 200 nM CCPA in wild type mice
LVSP (mmHg)
Male
(n=8)
Intact
Female
(n=6)
OvX
Female
(n=6)

+dP/dt (mmHg/sec)

-dP/dt (mmHg/sec)

Coronary Flow
(mL/min/g)
Baseline
CCPA

Baseline

CCPA

Baseline

CCPA

Baseline

CCPA

97 ± 2

106 ± 3*

3959 ± 182

4422 ± 228*

-2291 ± 115

-2563 ± 131*

18 ± 1

21 ± 2*

95 ± 7

99 ± 7*

3849 ± 480

4101 ± 521*

-2318 ± 289

-2509 ± 334*

23 ± 3

25 ± 3*

91 ± 2

94 ± 2

3421 ± 197

3546 ± 197

-2114 ± 106

-2212 ± 114

20 ± 2

22 ± 2*

Data are means ± SE, analyzed using a two-way ANOVA with repeated measures. LVSP- left ventricular
systolic pressure. *p<0.05 CCPA vs. baseline

Contractile responses to ISO following CCPA pre-treatment (shown in Figure 4) were
much reduced as compared to control ISO responses seen in Figure 3.

Intact females

demonstrated an enhanced A1AR anti-adrenergic effect as compared to males.

CCPA

pretreatment reduced the mean contractile response to 2 nM ISO by approximately 60% in males
and 90% in females (LVSP, +dP/dt and –dP/dt). With CCPA pre-treatment, intact female
contractile responses to ISO were significantly lower than male responses at all three doses in the
three contractile parameters (excluding +dP/dt at 1 nM). Coronary flow responses were only
reduced in intact females as compared to males at 10 nM ISO.

22
The potentiation of the A1AR anti-adrenergic effect in females was lost following
ovariectomy (40% reduction at 2 nM ISO in CCPA pre-treated as compared to control ISO
treatment). Following CCPA pre-treatment, contractile responses to ISO in hearts from OvX
mice were significantly greater than in hearts from intact females at both 2 and 10 nM ISO
(LVSP, +dP/dt and –dP/dt). Coronary flow responses were higher in OvX females as compared
to intact females at 2 and 10 nM ISO, with no differences at 1 nM ISO.

Figure 4- Hemodynamic responses to ISO with 200 nM CCPA pre-treatment. Presented as %
change from pre-ISO baseline in male (n=8), intact female (n=6) and ovariectomized female
(n=6) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, D- coronary flow). Data are means ± SE,
analyzed using two-way ANOVA with repeated measures. *p<0.05 intact female vs. male for
corresponding dose of ISO; †p<0.05 intact female vs. ovx female for corresponding dose of ISO.
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B. Modulation of βR Contractile Response by A1AR Deletion
Body weight was lower in age-matched A1 ARKO as compared to wild type (WT) males
(24 ± 1 vs. 28 ± 1 g), while it was higher in A1 ARKO as compared to WT females (23 ± 1 vs. 20
± 1 g). Additionally, while there were no differences in ventricular weight/body weight ratio in
A1ARKO versus WT males (4.8 ± 0.2 vs. 4.5 ± 0.1 mg/g), the ratio was significantly higher in
A1ARKO compared to WT females (5.6 ± 0.7 vs. 4.6 ± 0.1 mg/g).
As illustrated in Figure 5, deletion of the A1 AR resulted in potentiation of the βadrenergic contractile response in both males and females (as compared to Figure 3).

Figure 5- Hemodynamic responses to ISO in A1ARKO hearts. Presented % change from preISO baseline in male (n=3) and intact female (n=6) mouse hearts (A- LVSP, B- +dP/dt, C- dP/dt, D- coronary flow). Data are means ± SE, analyzed using a two-way ANOVA with
repeated measures. *p<0.05 A1ARKO female vs. A1 ARKO male
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In both male and female A1 ARKOs, the LVSP response at 1 nM ISO was enhanced by
92% versus their WT counterparts. Sex differences were not present in the contractile response
to ISO at any dose, in any parameter (LVSP, +dP/dt, -dP/dt). However, sample size may have
limited detection of significant sex differences, with p=0.0663 for LVSP and p=0.0879 for –
dP/dt, and adding more animals (particularly males) may have resulted in detection of a sex
effect in the A1ARKO response to ISO. There was a sex effect on the vascular response to ISO
in A1 ARKOs, with male dilation being greater than females. For example, at 1 nM ISO, the
percent increase in coronary flow in males was 39 ± 3%, and in females was 26 ± 3%.
C. Chronotropic and Vascular Actions of AR
There were no differences among males, intact females and ovariectomized females in
terms of baseline heart rate (in bpm: 339 ± 12, 333 ± 4 and 340 ± 16 respectively) or coronary
flow (in ml/min/g: 14 ± 1, 15 ± 1 and 15 ± 1). NECA administration resulted in potent decreases
in both heart rate (via the A1 AR) and coronary perfusion pressure (via the A2aAR and A2bAR).

Figure 6- Hemodynamic responses to NECA. Presented as % change from pre-NECA baseline
in male (n=3 at 0.5 and 1 nM, n=7 for 5 nM and higher), intact female (n=3 at 0.5 and 1 nM, n=6
for 5 nM and higher) and ovariectomized female (n=4) mouse hearts (A- heart rate and Bcoronary perfusion pressure). Data are means ± SE, analyzed using a two-way ANOVA.
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As shown in Figure 6, there were no sex differences in the heart rate or coronary
perfusion pressure responses to NECA. Additionally, ovarian hormone withdrawal in females
did not change heart rate or dilatory responses to NECA.
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Chapter 4: Modulation of the G Protein Signaling Pathway in the Isolated Heart- Methods
and Results
I. Rationale
The contractile responses elicited by β-adrenergic receptor activation occur in part due to
manipulation of downstream signaling pathways. The secondary hypothesis of this study was
that females would show altered expression or function of components of the βR system.
Pharmacological tools which manipulate components of the βR signaling pathway may be used
to alter their activity, and can address the possibility that males and females differ in expression
and/or function of proteins downstream of the β-adrenergic receptors.
Both the β1 and β2-adrenergic receptors couple to Gsα protein, and stimulate adenylyl
cyclase (AC) upon ligand binding. β2-adrenergic receptors can also couple to Giα protein, and
inhibit adenylyl cyclase upon their activation. When administered to the isolated heart, forskolin
elicits increases in contractility by directly activating adenylyl cyclase. Activation of the βR
signaling pathway results in stimulation of phosphodiesterases which hydrolyze cAMP, and the
nonselective phosphodiesterase inhibitor 3-Isobutyl-1-methylxanthine increases contractility in
the isolated heart by preventing degradation of cAMP. Functional responses to βR stimulation
are due in large part to actions of the second messenger cAMP, and a non-hydrolyzable analog of
cAMP (CPT-cAMP) was administered to the isolated heart to test if there are sex differences
downstream of cAMP which contributes to sex differences in the βR response.
II. Materials
KHB was purchased and prepared as described in Chapter 2. Forskolin (FSK), 3Isobutyl-1-methylxanthine

(IBMX),

and

8-(4-Chlorophenylthio)adenosine

3′,5′-cyclic

monophosphate (CPT-cAMP) (Sigma-Aldrich Inc, St Louis, MO) were prepared as 10 mM
stocks in DMSO and diluted as necessary. Final DMSO concentration in the perfusate was
<0.1%.
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III. Methods
A. Animal Model
Male and female mice were purchased and handled as described in Chapter 2.
B. Isolated Heart Preparation
Performed as described in Chapter 2. Baseline hemodynamic values were similar to
those reported in previous chapters.
C. Forskolin, IBMX and CPT-cAMP Dose Response Protocols
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the
experimental protocols. Hearts were administered forskolin (in nM 100, 300, 500, 750, 1000,
5000); IBMX (in μM 0.5, 1, 10, 25, 50, 100); or CPT-cAMP (in μM 5, 10, 25, 50). Steady state
responses in cardiac function and coronary flow were assessed after five minutes infusion of
each dose.
D. Data and Statistical Analysis
Performed as described in Chapter 2, using two-way ANOVAs with repeated measures.
IV. Results
A. Adenylyl Cyclase Activation in Males and Females
As shown in Figure 7, forskolin administration resulted in increases in both contractility
and coronary flow. There were no sex differences in the contractile response to forskolin in
terms of LVSP, +dP/dt or -dP/d. At 5 μM, the percent increase from baseline in LVSP was 77 ±
5 in males and 62 ± 5 in females; the percent increase from baseline in +dP/dt was 145 ± 5 in
males and 116 ± 10 in females, and the percent increase from baseline in -dP/dt was 129 ± 9 in
males and 105 ± 9 in females.
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Figure 7- Hemodynamic responses to forskolin. Presented as % change from pre-forskolin
baseline in male (n=8) and female (n=8) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and Dcoronary flow). Data are means ± SE, analyzed using two-way ANOVA with repeated
measures. *p<0.05 male vs. female
Male hearts showed greater dilatory responses to FSK administration than did female
hearts. For example, at 300 nM FSK, the percent increase from baseline in coronary flow in
males was 17 ± 2, and was 11 ± 2 in females.
B. Phosphodiesterase Inhibition in Males and Females
As shown in Figure 8, PDE inhibition with IBMX resulted in increases in both
contractility and coronary flow. There were no sex differences in the contractile responses to
IBMX.
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Figure 8- Hemodynamic responses to IBMX. Presented as % change from pre-IBMX baseline
in male (n=3) and female (n=3) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and D- coronary
flow). Data are means ± SE, analyzed using a two-way ANOVA with repeated measures.
Males showed a tendency toward greater coronary flow response to PDE inhibition at
higher doses of IBMX (p=0.0883). For example, at 25 μM IBMX, with males showing an
increase from baseline of 19 ± 2%, and females showing an increase from baseline of 11 ± 2%.
However, limited animal numbers prevented detection of statistical significance in this parameter.
C. Activation of cAMP-dependent Signaling in Males and Females
Activation of the cAMP signaling cascade using non-hydrolyzable analogue CPT-cAMP
resulted in increases in contractility and coronary flow. As shown in Figure 9, there were no
differences in the contractile responses to CPT-cAMP, in terms of LVSP, +dP/dt and –dP/dt.
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Figure 9- Hemodynamic response to CPT-cAMP. Presented as % change from pre-CPT-cAMP
baseline in male (n=3) and female (n=3) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and Dcoronary flow). Data are means ± SE, analyzed a two-way ANOVA with repeated measures.
While males showed a tendency toward greater dilatory responses at increasing doses of
CPT-cAMP than females, there were no statistically significant differences in flow responses
between sexes.

However, limited animal numbers likely prevented detection of statistical

significance in this parameter.
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Chapter 5: β-Adrenergic and Adenosine Receptor Gene Expression in Males, Intact
Females and Ovariectomized Females- Methods and Results
I. Rationale
The classical function of sex steroid hormones is modulation of gene transcription via
binding to their nuclear receptors. Sex differences in the expression of many genes have been
documented, and a role for sex steroid hormones in modulating gene expression has been shown
using gonadectomy models.
Since females exhibited a reduced β-adrenergic receptor contractile response as compared
to males, it was predicted that females could show reduced β1R expression as compared to males.
Additionally, intact females showed a dramatically enhanced A1 AR anti-adrenergic effect as
compared to both males and ovariectomized females. It was therefore predicted that intact
females may show an enhanced A1 AR expression and/or reduced A2aAR expression (which
antagonizes the A1AR).
To investigate receptor expression, Real Time RT-PCR was performed in both
ventricular tissue and ventricular myocytes.

This is a powerful technique used to assess

expression of a gene, quantified relative to an internal control gene. While it would be ideal to
assess expression of β-adrenergic receptor and adenosine receptor protein using western blotting,
severe limitations in the quality and specificity of antibodies for western blotting prevented this
method of analysis from being performed.

Several commercially available β1R and A1AR

antibodies were tested under different SDS-PAGE and western conditions. Multiple bands were
detected for the β1R, due to post-translational processing of the receptor (Rybin et al. 2000),
which complicates quantification. A1AR antibodies were tested using A1 ARKO tissue as a
negative control, and in all cases a band was detected at the predicted molecular weight for the
A1AR in both WT and KO tissue (though gene ablation was confirmed using PCR).
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II. Materials
A. Ventricular Myocyte Isolation
NaCl, KCl, KH2PO4, MgSO4, NaHCO3, HEPES, glucose, taurine, 2,3-butanedione
monoxime, sodium pyruvate, and Protease Type XIV were purchased Sigma-Aldrich, Inc (St
Louis, MO).

Collagenase Type B and Type D were purchased from Roche Diagnostics

(Mannheim, Germany).
B. RNA Isolation and PCR
Trizol reagent was purchased from Invitrogen (Carlsbad, CA). DNase I and the RNEasy
Mini Kit were purchased from Qiagen (Valencia, CA). All reagents necessary for reverse
transcription and real-time PCR were purchased from Applied Biosystems (Carlsbad, CA).
III. Methods
A. Ventricular Myocyte Isolation
Hearts were excised from anesthetized (Avertin, 400 mg/kg) and heparinized (500 units)
mice, placed in ice-cold saline and mounted on a perfusion apparatus. Hearts were perfused for
3-4 minutes at a baseline CPP of 60 mmHg with isolation buffer, in mM: NaCl 120, KCl 4.7,
KH2PO4 1.2, MgSO4 1.2, NaHCO3 5, HEPES 10, glucose 11, taurine 30, 2,3-butanedione
monoxime 10, sodium pyruvate 5, pH adjusted to 7.2 using NaOH. Isolation buffer was filtered
during the perfusion using a 0.22 μm in-line filter. Digestive enzymes were then added to the
isolation buffer, for a final concentration of 0.5 mg/ml Collagenase B, 0.5 mg/ml Collagenase D,
0.02 mg/ml Protease Type XIV and 50 μM CaCl2.

Flow was maintained constant unless

excessive vasoconstriction occurred at the early stage of digestive enzyme perfusion, at which
point flow was reduced, and then returned to baseline level as subsequent vasodilation occurred
(indicating digestion). Perfusion was performed for 10-14 minutes, until CPP was reduced to
<30 mmHg, indicating adequate digestion. Hearts were removed from the cannula, aorta and
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connective tissue was excised, and the remaining ventricular tissue was minced with
microscissors. The tissue was suspended in ~ 5 mL isolation buffer with 0.5% BSA and 50 μM
CaCl2, and gently dissociated with large and small tip plastic pipettes. The suspension was
filtered through cheesecloth into a 15 mL Eppendorf tube, and then allowed to settle by gravity.
The pellet (containing mostly rod-shaped myocytes) was resuspended in isolation buffer with
0.5% BSA and 100 μM CaCl2. Calcium concentration was slowly restored to 1.2 mM, and then
the cells were pre-plated in a tissue culture dish for 2 hours at 37°C. Following pre-plating, cells
were collected for RNA isolation.
B. RNA Isolation and Real Time Quantitative PCR
For gene expression analysis in ventricular tissue, hearts were rapidly excised and placed
in ice-cold saline, extraneous tissue (including atria) was removed, and the ventricular tissue was
flash frozen in liquid nitrogen and stored at -80°C until RNA isolation. For gene expression
analysis in ventricular myocytes, pre-plated cells were settled by gravity and the pellet was flashfrozen in liquid nitrogen and stored at -80°C until RNA isolation.
Total RNA was isolated using 1 mL of Trizol reagent. RNA was digested with DNase I
and purified using the RNeasy Mini Kit, according to the manufacturer’s instructions. RNA
quantity and quality was validated by spectrophotometry (i.e. A260/A280 ratio of ~2.2) and
agarose gel electrophoresis (presence of 18S and 28S RNA).

Reverse transcription was

performed on 1 µg of total RNA using the High Capacity cDNA reverse transcription kit. Gene
expression was assayed with TaqMan Universal PCR Master Mix and FAM-labeled TaqMan
inventoried gene expression assays according to manufacturer’s instructions. Real time PCR
was conducted using the StepOnePlus Real-Time PCR System. Data was analyzed by the
comparative 2-ΔΔCt method using GAPDH as an endogenous control (GAPDH showed no
difference in Ct values between males, intact females and ovariectomized females, data not
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shown). Expression of the gene of interest was calculated as fold difference relative to intact
females.
C. Data and Statistical Analysis
Data were analyzed with GraphPad Prism software and presented as means ± SE. Oneway ANOVAs were performed, with Post-hoc analysis using the Bonferroni’s method used
when necessary. Statistically significant differences in the values were taken at p < 0.05.
IV. Results
A. Gene Expression in Ventricular Tissue
There were no sex differences in the expression of β1R or β2R in ventricular tissue,
shown in Figure 10A.

Ovariectomy resulted in a modest decrease in β1R receptor gene

expression (0.72 ± 0.05 relative to intact female), with no changes in β2R gene expression.

Figure 10- Expression of β-adrenergic receptors (A) and adenosine receptors (B) in ventricular
tissue. n=5 for male, intact female and ovariectomized female mice. Data are expressed in fold
difference relative to intact female. Data are means ± SE, analyzed using one-way ANOVA.
*p<0.05 male vs. intact female, †p<0.05 intact female vs. ovariectomized female.
Intact females expressed a slightly, but significantly, higher level of the A1 AR gene in
ventricular tissue than both males and ovariectomized females (fold difference relative to intact
females: males 0.73 ± 0.07, OvX females 0.71 ± 0.02). There were no differences in the
expression of the other adenosine receptor subtypes.

35
B. Gene Expression in Ventricular Myocytes
There were no sex differences in the expression of either βR subtype in ventricular
myocytes. Additionally, ovariectomy did not alter the expression of either βR subtype (shown in
Figure 11A).

Figure 11- Expression of β-adrenergic receptors (A) and adenosine receptors (B) in ventricular
myocytes. Data are presented for wild type male (n=4), intact female (n=4) and ovariectomized
female (n=3) mice. Data are expressed in fold difference relative to intact female. Data are
means ± SE, analyzed using one-way ANOVA *p<0.05 male vs. intact female, †p<0.05 intact
female vs. ovariectomized female.
The enhanced A1 AR expression in female ventricular tissue was not seen in ventricular
myocytes (Figure 11B).

However, A3AR expression was greater in intact female myocyte

samples as compared to both males (0.52 ± 0.07 fold difference relative to intact females) and
ovariectomized females (0.61 ± 0.02 fold difference relative to intact females).
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Chapter 6: Expression of Components of the G Protein Signaling Pathway in Males and
Females- Methods and Results
I. Rationale
βR contractile responses were reduced in females as compared to males, and β1R and
β2R gene expression did not differ between males and females. While the possibility cannot be
excluded that receptor protein expression differs between males and females, the next point of
investigation into a potential mechanism for the reduced response to ISO in females was at the
level of expression of components of the βR signaling pathway.
Relevant subtypes of some of the targets assessed on the functional level in Chapter 4
were addressed at the level of protein expression. Namely, the predominant cardiac isoforms of
adenylyl cyclase are types V and VI (Ishikawaet al. 1997). PDE4D is expressed in cardiac
myocytes and has been demonstrated to modulate βR subtype-specific signaling (De Arcangelis
et al. 2010). Additionally, the expression of Gsα and Gi-2α (a form having been shown to couple
to the β2R) (Xaio et al. 1999) proteins, as well as protein phosphatase 1 and protein phosphatase
2A, were considered. If the expression of one or multiple components of the βR signaling
pathway were altered in females (as predicted in Hypothesis 2), it could help explain the reduced
βR contractile response in female hearts.
II. Materials
Isolation buffer and digestive enzymes were purchased and prepared as described in
Chapter 6. SIGMAFAST Protease Inhibitor Cocktail was purchased from Sigma Aldrich, Inc (St
Louis, MO). Phosphatase Inhibitor Cocktail was purchased from Nacalai Tesque (San Diego,
CA).

Materials for western blotting were purchased from BioRad (Hercules, CA).

Anti-

adenylyl cyclase V/VI, anti-Gsα protein, anti-Gi-2α protein and anti-phosphodiesterase 4D
primary antibodies were purchased from Santa Cruz (Santa Cruz, CA).

Anti-GAPDH

conjugated to horseradish peroxidase (HRP), anti-PP2A C subunit primary antibody, and goat
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anti-rabbit secondary antibody were purchased from Cell Signaling (Danvers, MA). Anti-PP1
antibody was purchased from Upstate/Millipore (Billerica, MA). Goat anti-mouse secondary
antibody was purchased from Jackson Immunoresearch (West Grove, PA).

Enhanced

chemiluminesence (ECL) was purchased from Pierce (Rockford, IL).
III. Methods
A. Animal Model and Ventricular Myocyte Isolation
Performed as described in Chapter 5.
B. Generation of Ventricular Myocyte Lysate
Following pre-plating, the myocyte suspension was spun at 1000 rpm for 15 seconds.
The isolation buffer was aspirated, and the cells were washed once with ice-cold buffer and spun
at 1000 rpm for 15 seconds. Cells were resuspended in lysis buffer: 50 mM Tris pH 7.4, 150
mM NaCl, 5 mM EDTA, 1% Triton-X 100, 1X SIGMAFAST protease inhibitor cocktail and 1X
Phosphatase inhibitor cocktail. Sonication was performed (3 quick bursts), and the lysate was
kept on ice for 20 minutes and vortexed every five minutes. The lysate was spun at 10,000g for
5 minutes, and the supernatant from this spin was stored at -80°C until study.

Protein

concentration was assayed using the Bradford method.
C. SDS-PAGE and Western Blotting
For all proteins of interest, 25 μg of myocyte lysate was loaded on a 10% polyacrylamide
gel, with lamelli buffer (final concentration of 1.25X SDS), and 10% β-mercaptoethanol.
Following SDS-PAGE, proteins were transferred to 0.2 μm nitrocellulose membranes. Protein
loading was assessed following transfer using Ponceau Stain. Membranes were blocked for 1
hour in 5% instant nonfat dry milk (Carnation) in TBS with 0.05% Tween-20 (TBST), then
washed three times with TBST. All antibodies were incubated overnight at 4°C in TBST with
1% milk with gentle rocking. The following primary antibody dilutions were used:
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Table 5- Primary antibody dilutions for western blotting
Protein Target
Dilution
Adenylyl cyclase V/VI (rabbit polyclonal)
1:100
Gsα protein (rabbit polyclonal)
1:1000
Gi-2α protein (rabbit polyclonal)
1:1000
PDE4D (rabbit polyclonal)
1:500
PP1 (mouse monoclonal)
1:500
PP2A (rabbit polyclonal)
1:500

Following overnight incubation with primary antibody, membranes were washed three
times with TBST. Membranes were then incubated for one hour at room temperature (gentle
rocking) with secondary antibody (goat anti-rabbit or goat anti-mouse), at a dilution of 1:5000
(excluding PP1, PP2A which required a secondary dilution of 1:2500), or loading control
GAPDH conjugated to HRP (1:5000), all in TBST with 1% milk. Membranes were then washed
three times with TBST, one time with TBS, and exposed to ECL for autoradiography. Due to the
molecular weight of PP1 and PP2A, these blots were stripped with glycine stripping buffer and
reprobed for GAPDH as described.
D. Data and Statistical Analysis
Quantification of band density was performed using UN-SCAN IT Gel Version 6.1. Data
were analyzed with GraphPad Prism software and presented as means ± SE. Data were analyzed
using an unpaired t-test. Statistically significant differences in the values were taken at p < 0.05.
IV. Results
For each protein of interest, the original blot and quantification of expression relative to
GAPDH (detected as a single band at the predicted molecular weight of 37 kD) is presented.
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Figure 12- Gsα protein expression in myocytes- quantification and original blot. n=5 myocyte
lysates for male and female. Expression is quantified relative to loading control GAPDH, with
data expressed as means ± SE.
A single band for Gsα protein was detected near the predicted molecular weight of 45 kD.
There were no differences in the expression of Gsα protein between males and females in
ventricular myocytes.

Figure 13- Gi-2α protein expression in myocytes- quantification and original blot. n=5 myocyte
lysates for male and female Expression is quantified relative to loading control GAPDH, with
data expressed as means ± SE.
A single band for Gi-2α protein was detected near the predicted molecular weight of 41
kD.

There were no differences in the expression of Gi-2α between males and females in

ventricular myocytes.
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Figure 14- Adenylyl cyclase V/VI expression in myocytes- quantification and original blot.
n=5 myocyte lysates for male and female. Expression is quantified relative to loading control
GAPDH, with data expressed as means ± SE. *p<0.05 female vs. male
Adenylyl cyclase V/VI was detected as a single band near the predicted molecular weight
of 132 kD. As shown in Figure 14, females express significantly higher levels of adenylyl
cyclase V/VI than males in ventricular myocytes (3.76 ± 0.74 vs. 1.52 ± 0.09).

Figure 15- Phosphodiesterase 4D expression in myocytes- quantification and original blot. n=5
myocyte lysates for male and female. Expression is quantified relative to loading control
GAPDH, with data expressed as means ± SE.
PDE4D was detected as a single band at a molecular weight of ~75 kD (predicted
molecular weight for various isoforms 65-119 kD). There were no differences in the expression
of PDE4D between males and females.
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Figure 16- Protein phosphatase 1 expression in myocytes- quantification and original blot. n=5
myocyte lysates for male and female. Expression is quantified relative to loading control
GAPDH, with data expressed as means ± SE.
Protein phosphatase 1 was detected as a single band at the predicted molecular weight of
38 kD. There were no differences in the expression of PP1 in ventricular myocytes between
males and females.

Figure 17- Protein phosphatase 2A expression in myocytes- quantification and original blot.
n=5 myocyte lysates for male and female. Expression is quantified relative to loading control
GAPDH, with data expressed as means ± SE.
A single band at the predicted molecular weight of protein phosphatase 2A was detected
(two forms exist at 36, 38 kD). There were no sex differences in the expression of PP2A in
ventricular myocytes.
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Chapter 7: cAMP Accumulation following βR Stimulation in Male and Female MyocytesMethods and Results
I. Rationale
Stimulation of the β-adrenergic receptors with ISO leads to increases in contractility via a
cAMP-dependent mechanism. It was predicted that sex differences in β-adrenergic receptor
responses to ISO occur at the level of the ventricular myocyte, the major contractile cell of the
heart. If the sex differences seen in the βR response are cAMP-dependent, determining the
extent cAMP accumulation in ventricular myocytes using an enzyme-linked immunosorbent
assay (ELISA) would detect these differences.
ISO stimulations that are performed for measurement of cAMP are often performed in
the presence of a phosphodiesterase inhibitor. As mentioned in the Background, PDE4 is
activated upon βR stimulation to prevent excessive generation of cAMP (and consequently
excessive contractile responses). Studies were therefore performed with and without the PDE4
inhibitor rolipram, in order to determine if PDE is more active in limiting cAMP generation in
females than males.
II. Materials
Isolation buffer, digestive enzymes, and ISO were purchased from companies described
in previous chapters. Rolipram was purchased from Tocris Bioscience (Minneapolis, MN). The
alkaline phosphatase cAMP Complete ELISA Kit was purchased from Enzo Life Sciences
(Farmingdale, NY).
III. Methods
A. Animal Model and Ventricular Myocyte Isolation
Performed as described in Chapter 5.
B. Drug treatment, Lysis and ELISA
Following pre-plating, the myocyte suspension was split into three 15 mL Eppendorf
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tubes, allowing for one vehicle-treated (phosphate buffered saline, PBS) myocyte population and
two drug-treated myocyte populations from a single heart. The tubes were spun at 1000 rpm for
15 seconds to obtain a myocyte pellet. Each pellet was resuspended in 3 mL isolation buffer
with 0.5% BSA, 1.2 mM CaCl2 along with the appropriate treatment (vehicle or drug). Cells
were treated with vehicle or a single dose of ISO (in nM: 1, 10, 100, 1000) for 10 minutes at
37°C. For PDE inhibition studies, cells were treated for 10 minutes with 1 μM rolipram prior to
as well as during ISO treatments. Following treatments, the tubes were placed on ice to arrest
the cells, and then spun at 1000 rpm for 15 seconds. Treatment buffer was aspirated, and the
cells were washed once with ice-cold buffer and spun at 1000 rpm for 15 seconds. The pellet
(myocytes) was resuspended in 350 μL 0.1 M HCl with 0.5% Triton-X 100, and left at room
temperature for 10 minutes for lysis. The lysate was spun at 800g for 10 minutes, and the
supernatant was stored at -80°C until study.

ELISA was performed according to the

manufacturer’s instructions. The 96-well plate was read using Molecular Devices SpectraMax
M2.

Protein concentrations for each lysate were assayed using the Bradford Method.

C. Data and Statistical Analysis
SoftMax Pro Version 5 Software provides a 4 parameter logistic curve fitting program for
quantification of cAMP concentration.

cAMP concentration was normalized to protein

concentration. Data were analyzed with GraphPad Prism software and presented as means ± SE.
Data were analyzed using two-way ANOVAs. Post-hoc analysis using the Bonferroni method
was performed when necessary. Statistically significant differences in the values were taken at p
< 0.05.
IV. Results
A. ISO Dose Response Studies
There were no sex differences in basal (i.e. PBS-treated) cAMP concentrations (1.73 ±
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0.19 pmol/mg protein in males, 2.17 ± 0.16 pmol/mg protein in females). ISO significantly
increase cAMP content as compared to vehicle.

Figure 18- cAMP accumulation following ISO treatment in myocytes. n≥4 per ISO dose. Data
are means ± SE, analyzed using a two-way ANOVA with Bonferroni post hoc analysis. *p<0.05
male vs. female; †p<0.05 ISO dose vs. vehicle
Females tended to show greater cAMP accumulation upon ISO treatment as compared to
males (p=0.0026 male versus female). For example, at the 10 nM dose of ISO female cAMP
content in pmol/mg protein was 5.88 ± 0.44 versus 4.20 ± 0.33 in males.
B. Effect of PDE Inhibition on cAMP Accumulation
Rolipram treatment (1 μM) did not alter cAMP concentration in male or female myocytes
(males= 2.15 ± 0.22 pmol/mg protein, females= 2.28 ± 0.22 pmol/mg protein).
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Figure 19- cAMP accumulation following ISO treatment with and without rolipram pretreatment in myocytes. n≥3 per ISO dose. Data are means ± SE, analyzed using a two-way
ANOVA with Bonferroni’s post hoc analysis. *p<0.05 rolipram male vs. rolipram female at 10
nM ISO; †p<0.05 ISO dose vs. vehicle; ‡p<0.05 rolipram vs. control
Phosphodiesterase 4 inhibition with rolipram pre-treatment did not significantly alter the
1 nM ISO response. However, rolipram pre-treatment did significantly increase the cAMP
accumulation at the 10 nM dose of ISO in both males and females. At the 10 nM dose of ISO,
rolipram pre-treated females showed a greater cAMP response than rolipram pre-treated males
(in pmol/mg protein: 16.06 ± 2.00 vs. 9.86 ± 1.72 respectively).
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Chapter 8- Signaling in Response to β-Adrenergic Receptor Stimulation in Male and
Female Myocytes- Methods and Results
I. Rationale
cAMP which is generated following βR stimulation activates protein kinase A, resulting
in the phosphorylation of multiple proteins which modulate the contractile state of the myocyte.
Two of these proteins which are phosphorylated by PKA following βR stimulation are troponin I
(TnI) at residue serine 23/24 and phospholamban (PLB) at residue serine 16. Both of these
proteins are involved in the positive lusitropic response to β-adrenergic receptor stimulation (as
described in the Background). Western blotting enables an analysis of the phosphorylation states
of these proteins before and after ISO treatment in both males and females.
Hypothesis 2 stated that females show an altered expression and/or function of proteins
which would result in their reduced contractile response to ISO. In this context, it was predicted
that females would show reduced phosphorylation responses to ISO in either one or both of these
proteins, which would contribute the reduced lusitropic response to βR stimulation in females.
II. Materials
Myocyte isolation materials, ISO and western blotting supplies were purchased as
described in previous chapters.

Anti-phospho-TnI (Ser 23/24) and TnI antibodies were

purchased from Cell Signaling (Danvers, MA). Anti-phospho-PLB (Ser 16) was purchased from
Millipore (Billerica, MA), and anti-PLB was purchased from Pierce Antibodies/Thermo
Scientific (Rockford, IL).
III. Methods
A. Animal Model and Ventricular Myocyte Isolation
Performed as described in Chapter 5.
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B. Drug Treatment and Preparation of Myocyte Lysate
Following pre-plating, the myocyte suspension was split into three 15 mL Eppendorf
tubes, allowing for vehicle (PBS) and two drug-treated myocyte populations from a single heart.
The tubes were spun at 1000 rpm for 15 seconds to obtain a myocyte pellet. Each pellet was
resuspended in isolation buffer with 0.5% BSA, 1.2 mM CaCl2 along with the appropriate
treatment (vehicle or drug). Cells were treated with vehicle or a single dose of ISO (10 or 100
nM) for 10 minutes at 37°C. The treatment buffer was aspirated, and the cells were washed once
with ice-cold buffer and spun again at 1000 rpm for 15 seconds. Cells were resuspended in lysis
buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton-X 100, 1X SIGMAFAST
protease inhibitor cocktail and 1X Phosphatase inhibitor cocktail. Sonication was performed (3
quick bursts), and the lysate was kept on ice for 20 minutes and vortexed every five minutes.
The lysate was spun at 10,000g for 5 minutes, and the supernatant from this spin was stored at 80°C until study. Protein concentration was assayed using the Bradford method.
C. SDS PAGE and Western Blotting
For TnI blots, 30 μg of protein was loaded onto 10% polyacrylamide gels, and for PLB
blots, 50 μg of protein was loaded onto 12% polyacrylamide gels. SDS-PAGE, transfer to
nitrocellulose, as well as membrane blocking and washing were performed as described in
Chapter 6. The following dilutions were used for phospho-antibodies: pTnI 1:1000 in TBST
with 2.5% BSA, pPLB 1:300 in TBST with 5% BSA. Goat anti-rabbit secondary antibody was
used at 1:5000 for pTnI detection, and 1:2000 for pPLB detection in TBST with 1% milk.
Membranes were stripped using glycine stripping buffer and reprobed for total TnI (1:5000
primary, 1:10000 goat anti-rabbit secondary), and total PLB (1:10,000 primary, 1:20,000 goat
anti-mouse secondary), all in TBST with 1% milk.
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D. Data and Statistical Analysis
Data were analyzed with GraphPad Prism software and presented as means ± SE. Data
were analyzed using two-way ANOVAs. Post-hoc analysis using the Bonferroni method was
performed when necessary
IV. Results
A. Troponin I Phosphorylation in Males and Females
There were no differences in vehicle-treated pTnI levels between males and females.
Both the original blot and quantified levels of pTnI relative to TnI are presented in Figure 20.

Figure 20- Phosphorylation of troponin I following ISO treatment in myocytes. Data are shown
for males (n=6) and females (n=5). Both the original blot and quantification (pTnI/TnI) are
presented. Data were analyzed using a two-way ANOVA. †p<0.05 ISO dose vs. baseline within
group
Both pTnI and TnI were detected as a single band near the predicted molecular weight of
28 kD. Note that ISO treatment resulted in large increases in troponin I phosphorylation as
compared to vehicle treatment. Interestingly, there were no sex differences in the extent of TnI
phosphorylation following ISO treatment. For example, at 10 nM the ratio of pTnI to TnI in was
0.52 ± 0.065 in male myocytes and was 0.56 ± 0.053 in female myocytes.
B. Phospholamban Phosphorylation in Males and Females
There were no differences in vehicle-treated pPLB levels between males and females.
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Both the original blot and quantified levels of pPLB/PLB are presented in Figure 21.

Figure 30- Phosphorylation of phospholamban following ISO treatment in male (n=6) and
female (n=5) myocytes. Both the original blot and quantification (pPLB/PLB) are presented.
Data were analyzed using a two-way ANOVA. *p<0.05 male vs. female at corresponding ISO
dose †p<0.05 ISO dose vs. baseline within group
Both pPLB and PLB were detected as a single band at the predicted molecular weight for
the monomeric form of the protein, ~5 kD. Note that ISO treatment resulted in increased
phospholamban phosphorylation as compared to vehicle only in the female samples.
Additionally, females showed a statistically greater PLB phosphorylation at the 100 nM dose of
ISO (pPLB/PLB ratio of 1.77 ± 0.20 in females vs. 1.00 ± 0.11 in males).
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Chapter 9: Discussion
I. Summary of Results
The previous chapters described the results of an investigation into sex differences in the
β-adrenergic contractile response. A summary of these findings is listed below:
1.

Females displayed a reduced contractile response to βR agonist isoproterenol as compared
to males in the isolated heart. Ovariectomy did not alter the contractile response to ISO.

2.

Females displayed an enhanced A1 AR anti-adrenergic effect as compared to males and
ovariectomized females, and sex differences in response to ISO were eliminated in
A1 ARKO hearts (though addition of more animals may have shown differences that were
reduced but not eliminated).

3.

There were no sex differences in the contractile responses to AC activation, PDE inhibition,
or stimulation of the cAMP pathway.

4.

There were no sex differences in βR or AR gene expression in ventricular myocytes.

5.

Females expressed significantly higher levels of ACV/VI in ventricular myocytes. There
were no sex differences in the expression of Gsα protein, Gi-2α protein, PDE4D, PP1 or
PP2A in ventricular myocytes.

6.

Females showed enhanced cAMP accumulation as compared to males, with and without
PDE4 inhibition.

7.

There were no sex differences in the phosphorylation of TnI following ISO treatment in
ventricular myocytes.

Females showed enhanced PLB phosphorylation following ISO

treatment in ventricular myocytes.
II. Sex Differences in the β-Adrenergic Contractile Response
Results indicated that sex differences exist in β-adrenergic contractile responsiveness.
Males exhibited enhanced contractile responses to ISO as compared to intact females.
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Ovariectomy did not alter the βR response in females. Males demonstrated greater vasodilation
upon β-adrenergic receptor stimulation than intact females, possibly due to the greater increase in
oxygen demand that accompanies greater contractile responses.
There is some debate in the literature regarding sex differences in cardiac β-adrenergic
receptor responsiveness. The results of studies in rat atrial and ventricular myocytes agree with
our findings that males show an enhanced β-adrenergic contractile response compared to females
(Curl et al. 2001; Schwertz et al. 1999; Vizgirda et al. 2002). In contrast, studies in isolated rat
trabeculae (Monasky et al. 2008) and rat papillary muscle (Chu et al. 2005) indicate that no sex
differences exist in β-adrenergic contractile responses.

These disparities may be due to

differences in experimental models, as well as the doses of ISO used. As shown in Figure 3, our
studies indicated that sex differences were greater at 1 nM and 2 nM ISO. At the high dose (10
nM), these differences were not as dramatic. Our study is the first in the isolated heart to show
that sex differences exist in the β-adrenergic contractile response at low doses of ISO. Our
observations were made at a physiological heart rate and physiological temperature, conditions
that were not used in previously cited studies.
Results also indicate that ovariectomy did not alter the β-adrenergic contractile response
in murine myocardium. This corroborates the findings of Chu and colleagues, who found that
ovariectomy did not change the contractile response to ISO over a wide range of doses in
isolated rat papillary muscles (Chu et al. 2006), as well as with those of Patterson and colleagues
using rabbit papillary muscles (Patterson et al. 1998). In contrast, Wu et al. reported that
ovariectomy increased basal contractility and β-adrenergic contractile responses in rat ventricular
myocytes (Wu et al. 2008). Differences in species, age at ovariectomy, time allowed for ovarian
withdrawal, as well as experimental model are likely to contribute to the contrasting findings.

52
III. Modulation of the βR Response by the A1 Adenosine Receptor
The anti-adrenergic actions of adenosine are well established. As discussed in Chapter 1,
adenosine reduces β-adrenergic receptor-mediated increases in myocyte contractility via the
A1AR. The results of the present study suggest that intact females display significantly greater
A1AR anti-adrenergic effects than males. This effect was observed in all contractile parameters
at all doses of ISO (excluding +dP/dt at 1 nM ISO). This is the first report to suggest that sex
differences exist in the A1AR anti-adrenergic effect. While β-adrenergic receptor responsiveness
did not change following ovariectomy, the A1AR anti-adrenergic effect did appear to be
modulated at least in part by ovarian hormones, as the enhanced anti-adrenergic effect seen in
females was lost following ovariectomy. Both limitation of adenylyl cyclase activity by Giα
protein (coupled to A1AR) and activation of protein phosphatases have been implicated in the
mechanism for the anti-adrenergic effect of adenosine (Dobson 1983; Gupta et al. 1993; Liu et al.
2002; Narayan et al. 2000; Neumann et al. 1989; Neumann et al. 1994; Romano et al. 1990), and
perhaps sex differences in either of these actions may contribute to the enhanced effect seen in
intact females.
The observed sex differences in A1 AR anti-adrenergic effect could play a role in the
reduced β-adrenergic receptor responsiveness observed in female hearts. There is evidence that
endogenous adenosine, which increases in concentration during stimulation of the β-adrenergic
receptor, acts through the A1AR to exert anti-adrenergic effects on contractility (Dobson et al.
1986; Dobson 1996).

This serves as a negative feedback mechanism to prevent extreme

responses to catecholamine stimulation. Our study is the first to report the potentiation of βadrenergic positive inotropic responses in A1ARKO mice compared to their WT counterparts.
As shown in Figure 5 (as compared to Figure 3), the contractile response to ISO was potentiated
in both A1ARKO males and females compared to wild type responses. The sex differences
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observed in the contractile responses to ISO in wild types was eliminated in A1 ARKOs, though it
is predicted that addition of more animals would suggest that males still appear to be greater
responders than females. This suggests that endogenous adenosine, acting through the A1AR,
may play a part in generating sex differences in the β-adrenergic contractile response. However,
it is unlikely that the A1 AR is the sole mediator in generating reduced βR responsiveness in
females, and subsequent experiments investigated other potential mechanisms in terms of the βR
signaling pathway.
After observing such a dramatic difference between males, intact females and
ovariectomized females in the A1 AR anti-adrenergic effect, an investigation into other roles of
adenosine receptor function was performed.

The non-selective adenosine receptor agonist

NECA promotes decreases in heart rate via the A1AR, as well as coronary vasodilation via the
A2aAR and A2bAR. In the present study, there were no sex differences in heart rate and coronary
perfusion pressure responses to NECA, and ovarian hormone withdrawal did not alter these
responses.
The negative chronotropic effects of NECA are mediated by the A1 AR, which slows
atrioventricular nodal conduction.

The results of this study suggest that there are no sex

differences in A1AR function in the conductive tissue of the heart, and this did not change in
females following ovariectomy.

Few studies have considered sex differences in adenosine

receptors-mediated modulation of heart rate. In two reports, Yang and colleagues note that the
effect of A1AR deletion on heart rate differed in males and females. In conscious mice being
studied using telemetry, deletion of the A1AR in females had little effect on heart rate, whereas
males showed increases in heart rate following A1 AR deletion (Yang et al. 2007; Yang et al.
2009). Their findings suggest that sex differences exist in the modulation heart rate by the A1 AR
when factors such as neuronal and hormonal inputs are present to modulate conduction.
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Coronary dilatory responses were seen at doses as low as 0.5 and 1 nM NECA, with
maximal dilation occurring at the 50 nM dose. Dilation at lower doses of NECA is mediated by
the high-affinity A2aAR, with dilation at higher doses of NECA being mediated by the lowaffinity A2bAR (Morrison et al. 2002). There were no sex differences in the NECA-induced
reductions in coronary perfusion pressure, suggesting no differences exist in A2aAR and A2bAR
function in the coronary vasculature under normal conditions. Few studies have considered sex
differences in adenosine receptor function in the vasculature. Our results correspond with the
finding that while the mechanism of adenosine-mediated dilation in porcine coronary arterioles
differs between males and females, their vasodilatory responses to adenosine did not (Heaps et al.
2002).
IV. G Protein Pathway Function in Male and Female Hearts
It was hypothesized that the expression and/or function of components of the G protein
signaling pathway would differ between males and females, contributing to sex differences in the
βR contractile response.

This study addressed the action of several components of the β-

adrenergic receptor signaling cascade in both sexes, and is the first to do so in the isolated
perfused heart. Since ovariectomy did not alter the βR response, this mechanistic investigation
was not performed in ovariectomized mice.

Several investigators have used β-adrenergic

receptor stimulation to assay cAMP accumulation, to address the possibility that myocardial
adenylyl cyclase activity may differ between males and females (Dent et al. 2011a, Schwertz et
al. 1999; Vizgirda et al. 2002). However, there is discrepancy in the literature regarding the
presence of sex differences in the expression and/or function of βR themselves. Administration
of forskolin specifically addresses the action of adenylyl cyclase and circumvents potential
differences in β-adrenergic receptors which could contribute differences in cAMP accumulation.
Our results indicate a slightly, but not significantly enhanced contractile response in males as
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compared to females in terms of LVSP (less dramatic in both + and –dP/dt). It is likely that
differences would be detected with addition of more animals. These data suggest that sex
differences may exist in adenylyl cyclase expression and/or activity, resulting in differential
contractile responses to forskolin, particularly at the high dose administered. These differences
were modest in comparison to the sex differences in the contractile response to ISO, and suggest
that the role for adenylyl cyclase in generating this difference is, if anything, minor. There was a
sex effect in coronary flow responses to forskolin, with males tending to show greater
vasodilation than females.

The cellular mechanism for adenylyl cyclase-mediated myocyte

contraction versus adenylyl cyclase-mediated vasodilation is likely different. It is also possible
that adenylyl cyclase expression and/or function could differ between males and females in
coronary vasculature, contributing to more dramatic differences observed in coronary flow
responses than in contractile responses.
Another potential mechanism for the sex difference in the myocardial β-adrenergic
receptor responsiveness could be differences in the phosphodiesterases (PDEs) which hydrolyze
cAMP. In dose-response studies with the non-selective PDE inhibitor IBMX, there were no
differences in the contractile or vascular responses between male and female hearts. There have
been no other studies addressing potential sex-dependent differences in myocardial PDEs.
However, Wang and colleagues noted that there were sex differences in the vascular endothelial
cell expression of PDE1A and PDE3B genes, and males showed no functional response to
PDE3B inhibition, while females did (Wang et al. 2010).

Another report noted that sex

hormones modulate PDE5 gene expression and the vascular response to PDE5 inhibition (Sejima
et al. 2009).

Our results suggest that there are no sex differences in PDE activity in the

unstimulated heart.
To address if there are any sex differences in the contractile response downstream of
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cAMP generation in the isolated heart, a non-hydrolyzable form of cAMP was administered.
There were no sex differences in the contractile responses to CPT-cAMP. This suggests that at
equivalent concentrations of cAMP, males and females show similar contractile responses. No
known studies have considered sex differences in the activation of the myocardial protein kinase
A signaling cascade by cAMP. These findings suggest that one or more components acting
upstream of the cAMP/protein kinase A phosphorylation cascade are likely responsible for the
contractile differences between males and females in the β-adrenergic response. Additionally,
though not statistically significant, there was a strong tendency for males to dilate to a greater
extent following CPT-cAMP administration as compared to females. This suggests that in an
otherwise unstimulated heart, downstream cAMP signaling in the vasculature may differ more
dramatically between the sexes than in myocytes.
V. β-Adrenergic Receptor and Adenosine Receptor Gene Expression
It was hypothesized that observed sex differences in β-adrenergic responsiveness could
be due to sex-dependent differences in β-adrenergic receptor expression. However, we observed
no sex differences in levels of either β1- or β2-adrenergic receptor gene expression in ventricular
tissue or ventricular myocytes. There are no other studies examining sex-dependent differences
in β-adrenergic receptor expression in mouse myocardium. Dent and colleagues saw no
difference in β1R or β2R gene expression in rat left ventricle, corroborating our findings in mouse
ventricle and myocytes (Dent et al. 2011a). Additionally, there are reports that β-adrenergic
receptor protein expression in the rat ventricle does not differ in males and females, as
determined by both immunoblotting (Chu et al. 2005) and radioligand binding (Dent et al. 2011).
Interestingly, in a more recent investigation Dent et al. found females express higher levels of
β1R protein, with no difference in mRNA, in rat left ventricle (Dent et al. 2011b). However, this
contrasts with other reports that males have greater β-adrenergic receptor density in rat left
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ventricular membranes (Bordallo et al. 2009; Vizgirda et al. 2002). Our results suggest that the
sex differences in response to β-adrenergic receptor stimulation are not due to differences in βadrenergic receptor expression, at the genetic level. However, the possibility cannot be ruled out
that differences in β-adrenergic receptor protein expression may exist between males and females.
Ovariectomy led to a slight reduction of ventricular β1-adrenergic receptor gene
expression as compared to intact females, but at the level of the ventricular myocyte there were
no differences in the level of βR expression.

Multiple studies have demonstrated that β1-

adrenergic receptor protein expression in rat ventricular membranes is increased after
ovariectomy (Klankalya et al. 1988; Thawornkaiwong et al. 2003; Wu et al. 2008), but no known
investigations have considered this in the mouse myocardium. Chu and colleagues showed that
β1-adrenergic receptor protein expression increased in rat ventricle following ovariectomy, but
this change in expression was not associated with an increase in the contractile response to ISO
(Chu et al. 2006). It appears that the slight decrease in cardiac β1-adrenergic receptor gene
expression that we observed in ovariectomized mice was not at the level of the ventricular
myocyte and had no significant functional effect in terms of the β-adrenergic contractile response.
Females expressed a significantly higher level of the A1AR gene as compared to males in
ventricular myocardium. However, this difference appears to be at the level of a non-myocyte
cell type, as no differences were seen in A1 AR gene expression in ventricular myocytes. A1AR
gene expression was similar in ovariectomized female and male ventricular tissue, but no
differences in A1AR gene expression were seen in intact vs. ovariectomized female myocytes.
These results suggest that long-term exposure to ovarian hormones modulates ventricular A1AR
gene expression in a non-myocyte cell type. In ventricular myocytes, A3AR gene expression was
significantly greater in intact females as compared to both males and ovariectomized females,
but there is no known role of the A3AR in modulating the β-adrenergic receptor contractile
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response.
It has been demonstrated that ovarian hormone withdrawal reduced A1 AR, A2aAR and
A3AR gene expression in the rat brain (Rose’Meyer et al. 2003). von Arnim and colleagues
reported no gender differences in A1AR and A3 AR gene expression in rat hippocampus using
reverse transcription PCR (von Arnim et al. 2002). There are no known investigations into
cardiac adenosine receptor gene expression in females, or the effects of ovarian hormone
withdrawal on cardiac AR gene expression. Additionally, limitations in adenosine receptor
antibodies prevented analysis of AR protein expression. It is acknowledged that adenosine
receptor protein expression could still differ between the groups to contribute to the observed
differences in the A1AR anti-adrenergic effect (i.e. enhanced A1 AR expression and/or reduced
A2aAR expression in intact females).
VI. Expression of Components of the G Protein Pathway in Myocytes
It was hypothesized that sex differences would exist in the expression of components of
β-adrenergic receptor signaling pathway that would lead to reduced contractile responses in
females (for example, enhanced Gsα protein or adenylyl cyclase in males, and/or enhanced
phosphodiesterase or protein phosphatase expression in females). The majority of the targets
assessed showed no difference in expression levels between males and females. Surprisingly,
ventricular myocytes from females express significantly higher levels of adenylyl cyclase type
V/VI than ventricular myocytes from males.

Dent and colleagues demonstrated no sex

differences in adenylyl cyclase type V/VI protein or mRNA levels in rat ventricular tissue (Dent
et al. 2011a; Dent et al. 2011b). The expression of ACV/VI has not been investigated in male vs.
female myocytes, nor has it been investigated in mouse myocardium in males vs. females. While
this was an interesting observation, it did not appear to have functional consequences in terms of
the contractile response to forskolin.
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The expression of Gsα and Gi-2α proteins were no different between males and females.
This had not previously been investigated in male vs. females in the heart. While the possibility
cannot be ruled out that coupling between βR and specific G proteins may differ between males
and females, it is clear that there were no sex differences in the expression of these proteins that
would contribute to sex differences in the response to ISO.
No sex differences were seen in PDE4D expression in ventricular myocytes.

As

mentioned previously, Wang and colleagues (Wang et al. 2010) noted that there were sex
differences in the vascular endothelial cell expression of PDE1A and PDE3B genes.
Additionally, another report noted that sex hormones modulate PDE5 gene expression. However,
this is the first known investigation into sex differences in protein expression of an isoform of
PDE, and the first to consider PDE expression in the cardiac myocyte in males vs. females.
PDE4D, the primary form involved with regulation of the βR signaling response, did not differ in
expression levels between males and females.
Expression of the two major serine/threonine protein phosphatases in the heart, PP1 and
PP2A, was also shown to be no different between males and females. These proteins regulate
phosphorylation states of targets of βR signaling, and no previous studies have addressed their
expression in both males and females. The present findings indicate that differences in the
expression of these two protein phosphatases do not appear to contribute to the reduced βR
contractile response in females.
VII. cAMP Accumulation Response to β-Adrenergic Receptor Stimulation in Myocytes
There was no sex difference in the basal cAMP concentration in ventricular myocytes.
Surprisingly, females tended to demonstrate greater cAMP accumulation upon ISO treatment
than males. Additionally, rolipram-pretreated females showed a greater cAMP response to 10
nM ISO than did males. The few investigators who have considered sex differences in adenylyl
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cyclase activity or cAMP concentration following βR stimulation have shown contrasting results.
Schwertz and colleagues, using left atrial tissue, found no sex difference in cAMP accumulation
following treatment with 300 nM ISO (Schwertz et al. 1999); Dent and colleagues saw no sex
difference in adenylyl cyclase activity following stimulation with 1 μM epinephrine in left
ventricular tissue (though they did see reduced basal adenylyl cyclase activity in females) (Dent
et al. 2011a). However, Vizgirda and colleagues found that rat ventricular myocytes from males
show a greater increase in cAMP concentration following treatment with 1 μM ISO than females
(Vizgirda et al. 2002). To our knowledge, no investigators have shown a greater cAMP response
to ISO in females than in males. However, no other group has performed these studies in mouse
myocytes. Additionally, we are the only group that performed these studies using lower doses of
ISO (and the most dramatic difference appeared to be at 10 nM ISO); perhaps other groups
would have made similar observations had they used low nM doses of ISO.
PDE4 inhibition with rolipram did not alter basal cAMP concentration, and it did not
enhance the 1 nM ISO treatment. However, cAMP concentration was significantly greater at 10
nM ISO in cells pre-treated with rolipram as compared to control cells. cAMP accumulation in
response to 10 nM ISO was still greater in PDE-inhibited females as compared to PDE-inhibited
males, suggesting that PDE activation upon βR stimulation is not responsible for the sex
differences in the cAMP response to 10 nM ISO.

None of the aforementioned studies

considering cAMP content in males vs. females mentioned if PDE inhibition was performed in
their analyses. Additionally, the phosphorylation and subsequent activation of PDE4 by PKA
has been demonstrated in non-cardiac cells (Sette et al. 1996), but has not been assessed in
cardiac myocytes. The extent of PDE phosphorylation has therefore not been investigated in
male vs. female myocytes.
It is possible that the enhanced adenylyl cyclase expression seen in female myocytes
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contributed to the enhanced cAMP accumulation response following βR stimulation at the 10 nM
dose. Interestingly, it has been demonstrated that increased expression of adenylyl cyclase type
VI via adenovirus in neonatal rat cardiac myocytes resulted in a proportional increase in βR
agonist-stimulated cAMP concentration (Gao et al. 1998). However, as previously mentioned,
the enhanced adenylyl cyclase expression in females does not appear to have functional
consequences at the level of the heart, as forskolin treatment showed essentially no sex
differences in contractile responses. The mechanism for the enhanced cAMP response to ISO in
females at 10 nM ISO remains unclear.
VIII. Phosphorylation of TnI and PLB following β-Adrenergic Receptor Stimulation in
Myocytes
There were no sex differences in the basal level of troponin I or phospholamban
phosphorylation between males and females. Additionally, there were no differences in TnI
phosphorylation following 10 minutes of treatment with 10 or 100 nM ISO. Surprisingly,
females showed enhanced phospholamban phosphorylation as compared to males at 100 nM ISO.
PKA-mediated phosphorylation of both troponin I and phospholamban is involved in the
positive lusitropic response elicited by β-adrenergic receptor stimulation.

There is some

controversy over the extent that these proteins play in enhancing the rate of myocyte relaxation
during βR stimulation (though these studies have been performed only in males).

The

importance of phospholamban in regulating calcium reuptake into the sarcoplasmic reticulum
and promoting relaxation is clear. It has been suggested that the role of TnI in promoting
relaxation via decreasing troponin sensitivity to calcium is less significant than that of PLB but
still important (Li et al. 2000). However, multiple groups have demonstrated that both PLB and
TnI phosphorylation play important roles in the lusitropic effects of ISO (Kentish et al. 2001;
Wolska et al. 2002; Yasuda et al. 2007), including a recent study demonstrating synergistic
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effects of TnI and PLB phosphorylation in promoting relaxation (Zhang et al. 2011).
It was hypothesized that females would show reduced phosphorylation states of the
targets of βR signaling, such as troponin I and phospholamban. Pott and colleagues showed no
differences in basal TnI phosphorylation states between murine males and females (Pott et al.
2008). Interestingly, Zhong et al. demonstrated no sex difference in basal phosphorylation of
PLB at residue serine 16, but the reduction in PLB phosphorylation that accompanies diabetes
was less pronounced in females than males (Zhong et al. 2003). However, to our knowledge, no
one has investigated βR signaling at the level of phosphorylation of these proteins in both males
and females.
It is unclear why females would show an enhanced phosphorylation response in PLB but
not TnI, as these proteins are phosphorylated by the same kinase and regulated by the same
phosphatases (Sulakhe et al. 1995). A kinase anchoring proteins (AKAPs) are involved in the
spatiotemporal modulation of signaling in the cardiac myocyte, serving as an integration site for
PKA with other kinase-mediated signaling pathways. TnI and PLB phosphorylation events are
controlled in part by the action of AKAPs (Fink et al. 2001), and no studies into sex differences
in AKAP function have been performed.

Studies into the regulation of PLB and TnI

phosphorylation have been performed only in males, and it is possible that differences in the
regulation of signaling between males and females could lead to this differential phosphorylation
response. Additionally, PLB and p-PLB were detected primarily in the monomeric form, but is
likely to exist in native SR membranes primarily in the pentameric form (Sulakhe et al. 1995),
and it is possible that the phosphorylation response to ISO may differ in monomeric vs.
pentameric PLB.
IX. Limitations
A robust analysis of the β-adrenergic receptor contractile response and signaling cascade
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in males and females was performed in this project. There are limitations to the studies that were
performed, and these limitations are listed below.
1. It is possible that a physiological disconnect exists between the results seen in an intact,
beating heart and quiescent, freshly isolated ventricular myocytes. It was predicted that a
mechanism for sex differences in the βR contractile response would be found at the level
of the myocyte, as this is the cell type responsible for contractile events. However, a
change in physiological properties in myocytes between intact myocardium and freshly
isolated myocyte may have prevented those differences from being observed.
Additionally, involvement of other cell types in the contractile effects seen in the isolated
heart cannot be ignored.
2. It is well-accepted that cAMP signaling, such as that which occurs during βR signaling, is
highly compartmentalized in the cell.

The technique used to quantify cAMP

concentration in a cell lysate may have overlooked sex differences in cAMP
compartmentalization.
3. Determining the expression of β1R and β2R, as well as the A1AR and A2aAR protein,
would be highly informative for this study. As mentioned previously, serious limitations
in specificity of the antibodies prevented their use in the study. While speculation on
expression levels may be made using Real Time PCR, gene and protein expression trends
do not always coincide, and knowledge of the level of protein would be helpful in
interpreting these data.
4. ISO is a non-selective β-adrenergic receptor agonist. Both β1R and β2R are capable of
altering cardiac contractility, but differ in their signaling, regulation and extent of
compartmentalization of signaling. To thoroughly address sex differences in the βR
contractile response, studies would also have to be performed using ISO in the presence
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of selective β1R and β2R antagonists.
X. Summary, Conclusions and Future Directions
The primary hypothesis of this study, that females display a reduced contractile response
to β-adrenergic receptor stimulation as compared to males in the isolated heart, was supported.
Ovarian hormone withdrawal did not alter this response in females. The secondary hypothesis of
this study was that females would show altered expression and/or function in components of the
β-adrenergic receptor signaling pathway which would contribute to this response. However, this
was not supported, and the mechanism for the reduced response to ISO in females remains
unclear. Rather, females appear to show a compensatory response to reduced βR responsiveness
in isolated myocytes: increased expression of adenylyl cyclase type V/VI, enhanced cAMP
accumulation upon ISO treatment, and enhanced phospholamban phosphorylation.
It is possible that sex differences in the response to ISO occur due to differential
regulation of calcium in male versus female ventricular myocytes. Chu et al. demonstrated that
females express higher levels of Cav1.2, ryanodine receptor and sodium-calcium exchanger in
rat ventricle, all proteins involved in calcium regulation (Chu et al. 2005). Others have shown
reduced amplitudes of calcium transients under both basal and ISO-stimulated conditions in
females (Chen et al. 2003; Farrell et al. 2010; Wasserstrom et al. 2008). Indeed, Chen and
colleagues demonstrated that females show reduced sarcoplasmic reticulum calcium loading
after treating rat ventricular myocytes with ISO, which they attribute to greater nitric oxide
generation in females as compared to males (Chen et al. 2003).

Our finding that PLB

phosphorylation is enhanced in females does not support these conclusions, but species
differences as well as dose and timing of ISO treatment may contribute to this disagreement.
It is likely that the mechanism for reduced β-adrenergic receptor contractile responses in
female hearts is multifaceted. Future studies should address the ideas of differential contribution
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of β1R vs. β2R to the response to non-selective agonist ISO in males and females, as well as how
cAMP signaling and calcium transients which occur when these receptors are stimulated differ
between males and females.

Additionally, the studies that were performed in ventricular

myocytes should also be performed in ventricular tissue, to address the possibility that changes
in physiology that occur during and following myocyte isolation may have altered βR responses.
For example, it would be predicted that phospholamban phosphorylation would be enhanced in
males upon ISO treatment in the ventricle, which would be necessary for enhanced relaxation in
males as compared to females, but this wasn’t detected in myocytes. Finally, the possibility that
other cell types may contribute to the observations made in the ventricle, such as vascular
endothelial cells, should not be ignored. These cells express both βRs and ARs, and co-culture
studies using ventricular myocytes and endothelial cells could address if interactions between
cell types contribute to differential responses to ISO in the heart.
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Premenopausal females are at a reduced risk for developing cardiovascular disease as
compared to males; this sex difference is not present following menopause.

β-adrenergic

receptors are pharmaceutical targets in the treatment of cardiovascular disease, and sex
differences in β-adrenergic responsiveness have been demonstrated. However, limited studies
have addressed the mechanism(s) underlying these differences.

To investigate these sex

differences, studies were performed using isolated perfused hearts from male, intact female and
ovariectomized female mice, as well as male and female ventricular myocytes. Female hearts
exhibited blunted contractile responses to the β-adrenergic receptor agonist isoproterenol (ISO)
compared to males but not ovariectomized females. The role of the A1 adenosine receptor
(A1AR) in antagonizing the β-adrenergic contractile response was investigated using the A1 AR
agonist CCPA and A1AR knockout (KO) mice. Intact females showed an enhanced A1 AR antiadrenergic effect compared to males and ovariectomized females. The β-adrenergic contractile
response was potentiated in male and female A1 ARKO hearts, with sex differences no longer
present. Forskolin (FSK), IBMX and CPT-cAMP dose response studies were performed in the
isolated heart to investigate the role of adenylyl cyclase, phosphodiesterase and the cAMP
signaling cascade, respectively, in generating sex differences in the β-adrenergic contractile
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response. There were essentially no sex differences in the contractile responses to FSK, IBMX or
CPT-cAMP. There were no sex differences in the expression of the β1R, β2R, or A1AR gene in
ventricular myocytes, nor were there differences in the expression of Gsα protein, Gi-2α protein,
PDE4D, PP1 or PP2A as determined with western blotting.

Adenylyl cyclase V/VI was

expressed in significantly higher levels in female myocytes. Females showed enhanced cAMP
accumulation upon ISO treatment with and without PDE4 inhibition. No sex differences were
present in troponin I phosphorylation at 10 or 100 nM ISO, while females displayed enhanced
phospholamban phosphorylation only at 100 nM ISO. Females appear to show compensatory
increases

in adenylyl cyclase expression,

cAMP

accumulation and

phospholamban

phosphorylation. The mechanism(s) for the reduced β-adrenergic contractile response in female
hearts remains unresolved.
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